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Die Akute Myeloische Leukämie (AML) ist eine sowohl zytogenetisch als auch 
molekulargenetisch äußerst heterogene Erkrankung, die durch die klonale Proliferation 
myeloider Vorläuferzellen sowie eine Ausreifungsblockade charakterisiert ist. Trotz des in den 
letzten Jahren zugenommenen Wissens über die Biologie dieser Erkrankung und 
Weiterentwicklung von Therapiemethoden bleibt das Gesamtüberleben der Patienten mit AML 
überwiegend schlecht. Damit für mehr Patienten eine Heilung der AML möglich werden kann, 
sind ein tieferes Verständnis über die funktionellen Zusammenhänge in der Leukämogenese, 
eine bessere Risikostratifizierung und neue Therapieoptionen erforderlich.  
Diese Habilitationsschrift fasst Publikationen zusammen, die neue molekulare Biomarker und 
deren klinischen Einfluss in der AML untersucht haben. Der Fokus liegt auf der Erfassung 
molekularbiologischer Veränderungen bei Diagnose einer AML oder im Krankheitsverlauf, die die 
Risikostratifizierung der Patienten verbessern kann. Außerdem gestattet die Arbeit Einblicke in 
die mit diesen molekularen Markern verbundene Biologie der AML, sowie mögliche neue 
Therapieoptionen.  
Der erste bis dritte Abschnitt der Arbeit fokussiert sich auf Genmutationen und Genexpressionen 
in der AML. Es wird dargelegt, wie das Vorhandensein bestimmter Fusionstranskripte (hier 
CBFB-MYH11), rekurrenter Mutationen allein (hier im DNMT3A Gen) sowie als Teil genetischer 
Risikoklassifikationssysteme (hier die genetischen Risikogruppen des European LeukemiaNet) 
und die abberrante Expression AML-assoziierter Gene (hier BAALC, ERG und MN1) Beiträge 
zur Prognoseabschätzung der AML bieten.  
Darüber hinaus hat sich in den letzten Jahren die entscheidende Rolle von MicroRNAs in der 
Pathophysiologie der AML herausgestellt. Heute weiß man, dass für die Leukämieentstehung 
und die Aggressivität der Erkankung schon die Dysregulation einer einzelnen microRNA 
entscheidend sein kann. Im vierten Abschnitt wird auf den progostischen Einfluss der 
Expressionslevel zweier MicroRNAs – miR-181a und miR-29b – und deren klinische und 
biologische Konsequenzen eingegangen. Außerdem wird dargestellt, wie verschiedene 
therapeutische Interventionen zu günstigen Änderungen des Expressionsniveaus dieser beiden 
neuen Biomarker und so zu potentiell neuen Therapiestrategien in der AML führen können.  
Weiterhin wächst die Erkenntnis, dass in der AML so gennannte Leukämie-initiierende Zellen 
für Therapieresistenz und Rezidive verantwortlich zu sein scheinen. Der letzte Abschnitt dieser 
Habilitationsschrift fokussiert sich auf das CD34+/CD38- Zellkompartiment, welches einen 
Großteil der Leukämie-initiiernden Zellen enthält. Es wird gezeigt, dass die Bestimmung der 
Größe des CD34+/CD38- Zellkompartiments bei Diagnose geeignet ist, AML Patienten mit 
einem erhöhten Rezidivrisiko nach allogener Stammzelltransplantation zu identifizieren. 
Zusammenfassend zeigt die Arbeit verschiedene Ansätze, wie neue molekulare Biomarker zu 
einer besseren Risikostratifizierung und einem tieferen Verständnis der AML zugrunde 
liegenden Biologie führen können. Des Weiteren beschreibt sie Möglichkeiten der 
therapeutischen Intervention und weist insgesamt auf die klinischen Implikationen dieser neuen 
Biomarker hin.   
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1. INTRODUCTION / EINFÜHRUNG IN DIE THEMATIK 
1.1. Diagnosis 
Acute myeloid leukemia (AML) is the most frequently diagnosed acute leukemia in adults, often 
affecting older individuals with a median age at diagnosis in the late 60’s.1-5 AML originates from 
the clonal expansion of myeloid progenitor cells that lost their ability to mature. Subsequently, 
healthy hematopoietic stem cells (HSCs) are displaced and unable to provide sufficient 
formation of peripheral blood cells. At diagnosis, AML patients present with a variety of non-
specific symptoms, which mostly are a result of peripheral cytopenia (i.e. anemia, 
thrombocytopenia and neutrophilopenia) and dysfunctional leukocytes, including fatigue, 
weekness, bleeding, and infections.1-5  
 
AML diagnosis requires the myeloid blast count to exceed 20%	 in bone marrow or peripheral 
blood, with the exception of AML with t(15;17), t(8;21), inv(16) or t(16;16), which represent AML 
defining cytogenetic changes.4,5 Flow cytometric analysis for surface markers (cluster of 
differentiation, CD) may aid in establishing the diagnosis of AML, as well as in defining mixed-
phenotype acute leukemias.5,6 While traditionally, the morphologic characterisation within the 
French American British Classification (FAB) was commonly used,7 over the last years the 
prognostic importance of cytogenetic and moleculargenetic characterisation became clearer, 
proofed to be more objective and consequently replaced the FAB classification.5 The majority of 
AML cases arise as de novo disease. However, AML might also develop as secondary disease 
originating from other hematologic disorders (e.g. myelodysplastic syndromes, 
myeloproliferative neoplasia) or after cytotoxic therapy of unrelated neoplasms (therapy-related 
AML).1-5 AML is a clinically highly heterogeneous disease, with a variable disease course and 
prognosis, which is thought to be based on differences in clinical features such as patient age, 
performance status and comorbidities, as well as leukemia-specific features including 
cytogenetics or presence of moleculargenetic and epigenetic changes.1-5  
 
 
1.2 Treatment and prognosis 
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Current outcomes with standard treatment approaches remain highly unsatisfactory. Today, 
only up to aproximatly one third of adult patients under the age of 60 years and only about 15% 
of patients over the age of 60 years achieve long-term survival.5 However, older or medically 
unfit patients not eligible for intensive chemotherapy, in general have median survival times of 
only about 5 - 10 months.5 Treatment of AML has changed little over the past decades. Curative 
treatment approaches remain to include the administration of the nucleoside analog cytarabine 
in combination with anthracyclines as induction therapy, followed by repeated cycles of high-
dose cytarabine and/or an autologous or allogeneic hematopoietic stem cell transplantation 
(HSCT).5,8,9 It is only very recently that a deeper understanding of AML biology started to 
provide us with novel therapeutic strategies, e.g. the introduction of tyrosine kinase inhibitors.10 
However, today only few of these agents are available in clinical routine and most are still being 
tested in clinical trials.5 For frontline treatment in older and medically unfit AML patients the 
administration of hypomethylating agents such as decitabine or acazitidine is often 
recommended and used. These treatments result in survival benefits but rarely produce long 
lasting remissions.5 
 
After achievement of a complete remission (CR) following induction chemotherapy, allogeneic 
HSCT is an established form of consolidation therapy for patients at high risk of relapse with a 
suitable donor available.8,9 The therapeutic effects of an allogeneic HSCT are also based on an 
immunologic graft-versus-leukemia (GvL) reaction.11 Furthermore, with the introduction of non-
myeloablative conditioning regimes that greatly reduced the toxicity of high doses of 
chemotherapy and/or radiation and have a greater reliance on GvL effects, allogeneic HSCT 
also became available for older and medically constrained patients.11,12  
 
1.3 Current risk assessment 
Over the past years, the cytogenetic and molecular characterization of AML to determine 
phenotype aggressiveness has steadily improved.5,13,14 Still, optimisation of risk-adapted 
treatment strategies are of high importance and remain an everyday challenge for clinicians. 
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Today, numerous prognosticators facilitate decisions on therapy de-escalation or intensification, 
enrolment in studies testing new agents, and the decision of appropriateness of an allograft 
procedure in first CR with its subsequent treatment-related morbidity, mortality, and financial 
costs.5   
 
Cytogenetic abberations are among the strongest known prognostic parameters in AML.5,15  
About 60% of AML patients show cytogenetic aberrations and for some of these abnormalities a 
strong prognostic impact on CR achievement, cumulative incidence of relapse (CIR) and overall 
survival (OS) has been shown.5,15 About 25% of younger adult AML patients present with 
cytogenetic aberrations known to associate with a favorable prognosis. These include the 
translocation t(15;17)(q22;q21) in acute promyelocytic leukemia (APL) and the inv(16)(p13q22) / 
t(16;16)(p13;q22) and t(8;21)(q22;q22) in the core-binding factor (CBF) leukemias.5,15 These 
individuals can expect CR rates over 90% and long-term survival in up to 65% of cases. On the 
other hand, in about 20% of AML adverse-risk cytogenetics, e.g. monosomies of chromosome 5 
(-5), abnormalities of 3q [abn(3q)] and monosomal or complex karyotypes, are found. In patients 
harboring these adverse-risk cytogenetics, CR rates in 65% and long-term survival in only 10% 
of cases can be exprected. Finally, in approximately 40-50% of newly diagnosed AML, no 
chromosomal aberrations can be found and despite their homogenous genetic appearance (46, 
XX or XY, normal cytogenetics, CN) clinical outcome in these patients proved highly 
heterogeneous.15  
 
The desire to further dissect the heterogenous outcome of CN-AML patients and to improve 
risk-stratification in this large AML subgroup let to the identification of important recurrent 
mutations in AML. Among these are mutations in the nucleophosmin-1 (NPM1) gene, which is 
one of the most commonly mutated genes in AML. NPM1 mutations are present in up to 20% - 
50% of AML cases, depending on the subgroups investigated.16-23 In the latest update of the 
World Health Organization (WHO) classification for AML, NPM1 mutations represent a distinct 
entity and commonly indicate a more favorable prognosis.5,15-23 Approximately one third of AML 
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patients carry an internal tandem duplications in the FLT3 gene (FLT3-ITD), resulting in a 
constitutive activation of several downstream FLT3 pathways. The presence of a FLT3-ITD, 
especially with a higher mutated-to-wildtype allelic ratio (≥ 0.5), is associated with a dismal 
prognosis, with a high risk of relapse even after allogeneic HSCT.24-29 The prognostic impact 
along with the observation that FLT3 is frequently overexpressed in a large subset of AML 
cases has let to the development of FLT3-targeting strategies, and today several FLT3 kinase 
inhibitors are being tested in clinical trials.5,30,10 Among the most studied proteins in AML is the 
CCAAT/enhancer-binding protein alpha (C/EBPα), a transcription factors that is important for 
myeloid differentiation. In AML, the encoding gene CEBPA frequently exhibits mutations, 
deregulation of expression or other functional alterations. CEBPA mutations lead to an altered 
C/EBPα function, affecting expression of downstream genes and consequently deregulated 
myelopoiesis.31 Detecting CEBPA mutations at diagnosis identifies patients with better 
outcomes, especially in the double mutated patients, and particularly in the molecular high-risk 
group (defined by presence of a FLT3-ITD and NPM1 wild-type), thus improving molecular risk-
based classification of AML.32-38  
 
The growing knowledge of molecular changes e.g. cytogenetics, recurrent mutations, or the 
aberrant expression of coding and non-coding genes not only allows us to improve risk 
stratification, but may also enable re-definition of risk-adapted treatment strategies in AML 
patients. It also helps us to better understand the underlying pathogenesis that leads to the 
development of AML. Current research also focuses on how we can exploit this knowledge to 
develop novel targeted therapies for each patient that finally may result in improved cure rates 
of the disease.  
 
In 2010 an international expert panel of the European LeukemiaNet (ELN) provided updated 
evidence and expert opinion-based recommendations for the diagnosis and management of 
AML.39 The standardized reporting system integrated molecular genetic data of the three genes 
mentioned above (i.e. NPM1, CEBPA, FLT3-ITD) into the known diagnostic information of 
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cytogenetics (Table 1). Subsequently, also a prognostic impact of the suggested standardized 
reporting system was demonstrated for AML patients focusing on chemotherapy 
consolidation.40,41 
 
Table 1 (Adapted from Döhner et al.)39: Cytogenetic and molecular genetic risk 
classification in AML according to the 2010 ELN reporting system 
 
Genetic group Subsets 
 
Favorable 
 
t(8;21)(q22;q22); RUNX1-RUNX1T1  
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
Mutated NPM1 without FLT3-ITD (normal karyotype)  
Mutated CEBPA (normal karyotype) 
 
Intermediate-I 
 
Mutated NPM1 and FLT3-ITD (normal karyotype)  
Wild-type NPM1 and FLT3-ITD (normal karyotype)  
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
 
 
Intermediate-II 
 
 
t(9;11)(p22;q23); MLLT3-MLL  
Cytogenetic abnormalities not classified as favorable or adverse 
 
 
Adverse 
 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 t(6;9)(p23;q34); 
DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
–5 or del(5q)  
–7 abnl(17p)  
Complex karyotype*  
 
 
* Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or inversions, 
that is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3) or t(3;3); indicate how many complex karyotype 
cases have involvement of chromosome arms 5q, 7q, and 17p 
 
 
Since then, additional frequent and recurrent mutations have been identified (e.g. in the 
DNMT3A, IDH1 and IDH2 genes) in AML.42-48 The continuous development of next-generation 
sequencing and other methods to detect genetic and epigenetic changes allowed to further 
characterize the biological AML background. However, the genetic profiling of AML is 
heterogeneous and only a few mutations (e.g. FLT3, NPM1, DNMT3A) are present in more than 
a quarter of AML patients.5 
 
Very recently, the ELN recommandations for the diagnostic work-up in AML have been updated 
and now include screening for mutations in NPM1, CEBPA, and RUNX1 genes, mutations in 
FLT3 (activating mutations of FLT3 may also benefit from tyrosine kinase inhibition), and 
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mutations in TP53 and ASXL1, since they consistently have been associated with poor 
prognosis (Table 2).5,49-60 
 
Table 2 (Adapted from Döhner et al.)5: 2017 European LeukemiaNet risk stratification by 
geneticsa 
 
Risk Categoryb Genetic Abnormality 
 
Favorable 
 
t(8;21)(q22;q22); RUNX1-RUNX1T1  
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow (c) 
Biallelic mutated CEBPA 
 
Intermediate 
 
Mutated NPM1 and FLT3-ITDhigh (c) 
Wild-type NPM1 without FLT3-ITD or FLT3-ITDlow (c) (without 
adverse-risk genetic lesions) 
t(9;11)(p22;q23); MLLT3-KMT2Ad 
Cytogenetic abnormalities not classified as favorable or adverse 
 
 
Adverse 
 
t(6;9)(p23;q34.1); DEK-NUP214 
t(v;11q23.3); KMT2A rearranged 
t(9;22)(q34.1;q11.2); BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM (EVI1)  
-5 or del(5q); -7; -17/abn(17p) 
Complex karyotype,e monosomal karyotypef 
Wild-type NPM1 and FLT3-ITDhigh  
Mutated RUNX1g 
Mutated ASXL1g 
Mutated TP53h 
 
 
a Frequencies, response rates and outcome measures should be reported by risk category, and, if sufficient numbers are available, 
by specific genetic lesions indicated.  
b Prognostic impact of a marker is treatment-dependent and may change with new therapies.  
c Low, low allelic ratio (<0.5); high, high allelic ratio (>0.5); semi-quantitative assessment of FLT3-ITD allelic ratio (using DNA 
fragment analysis) is determined as ratio of the area under the curve (AUC) “FLT3-ITD” divided by AUC “FLT3-wild type”;  recent 
studies indicate that acute myeloid leukemia with NPM1 mutation and FLT3-ITD low allelic ratio may also have a more    favorable 
prognosis and patients should not routinely be assigned to allogeneic hematopoietic-cell transplantation.  
d The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations. 
e Three or more unrelated chromosome abnormalities in the absence of one of the World Health Organization-designated recurring 
translocations or inversions, i.e., t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCR-ABL1. 
f Defined by the presence of one single monosomy (excluding loss of X or Y) in association with at least one additional monosomy 
or structural chromosome abnormality (excluding core-binding factor AML). 
g These markers should not be used as an adverse prognostic marker if they co-occur with favorable-risk AML subtypes.  
h TP53 mutations are significantly associated with AML with complex and monosomal karyotype.  
 
1.4 AML-associated gene expression  
Apart from recurrent mutations at diagnosis, expression levels of some AML-associated genes 
e.g. brain and acute leukemia, cytoplasmatic (BAALC), ETS-related gene (ERG), and 
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meningioma-1 (MN1) have been shown to have strong, independent prognostic impact in AML 
patients. 
High expression of the gene BAALC consistently associated with worse outcomes in younger 
and older patients with AML.61-63 This gene maps to chromosome band 8q22.3, is highly 
expressed in CD34-positive bone marrow progenitor cells and downregulated during 
hematopoietic lineage-specific maturation.61,62 Although it’s function in hematopoiesis is still not 
fully understood, there ist evidence that BAALC blocks myeloid differentiation and may 
contribute to leukemogenesis when co-occuring with a second molecular alteration providing a 
proliferation advantage.64 The gene ERG, located at chromosome band 21q22.3, was first 
shown to be involved in leukemogenesis in the rare, but recurrent in AML t(16;21)(p11;q22).65  
Moreover, ERG overexpression was demonstrated in AML patients with complex karyotypes 
with cryptic amplification of chromosome 21.66 It was also found overexpressed in part of 
patients with CN-AML where it contributes to poor prognosis in younger and older CN-AML 
patients.67-71 The MN1 gene is localized at human chromosome band 22q12 and encodes a 
transcriptional coregulator.72 MN1 is involved in myeloid malignancies as a fusion partner of the 
ETV6 gene in the recurrent translocation t(12;22)(p13q11)73 and has been shown to be 
overexpressed in subsets of AML.74,75 Different studies have shown that high MN1 expression 
levels are prognosticators for poor outcome in younger and older CN-AML patients.76-78 
 
The exploration of diagnostic expression levels of these AML associated genes provides 
important additional information for risk stratification and treatment strategies. However, the 
differential expression of these genes may also contribute to AML leukemogenesis. For 
example, Heuser et al.79 demonstrated that MN1 upregulation is involved in development of 
resistance mechanisms against all-trans retinoic acid (ATRA), an agent commonly used in APL 
treatment. Furthermore, they showed MN1 leukemogenecity to cooperate with a MEIS1/AbdB-
like HOX-protein complex, representing a possible therapeutic target in high MN1 expressing 
leukemias.80 
1.5 microRNAs in AML 
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Besides the aberrant expression of coding genes the differential expression of microRNAs 
(miRs) – small, non-coding RNAs – have been identified to play important roles in the initiation 
and progression of various malignancies, including AML.81,82 MiRs are essential for many 
biological processes by controlling the expression of a number of genes involved in commitment 
and differentiation of HSCs, proliferation, apoptosis, immune response, and 
leukemogenesis.81,82 
 
Over the past years, progress has been made in understanding the significance of expression 
levels of some miRs in AML. MiR expression profiles associated with outcome and certain 
molecular aberations in AML which have shed light on AML biology and also aid in refining AML 
risk stratification.81,82 As an example Marcucci et al. identified a miR signature that is associated 
with clinical outcome in a subgroup of patients with high-risk molecular features of AML (those 
who have FLT3-ITD, wild-type NPM1, or both).82 These data suggested that there is a functional 
relationship between miR expression and disease biology in AML patients that may render miR 
expression levels suitable prognostic markers and will help to further identify important players 
in AML biology.  
 
However, a more comprehensive understanding of miR expression within the complex 
regulatory networks that are disrupted in AML cells is necessary for the development of better 
prognostic systems and novel therapeutic strategies employing miR modulators to improve 
patients’ outcomes. 
 
1.6 Leukemia-initiating cells 
Another focus of current research in AML lies on the cells of AML origin. AML is a disease 
developing from the clonal expansion of early progenitor cells or HSCs that lost the ability to 
mature1 – often termed leukemia initiating cells – which are believed to exists within the 
CD34+/CD38- stem cell compartment.83-86 Leukemia initiating cells are postulated to survive 
chemotherapy as measurable (minimal) residual disease and cause AML relapse; their non-
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proliferative state might be one reason for their resistance to chemotherapy.87-90 Some studies 
have suggested that a high burden of leukemia initiating cells at diagnosis of AML patients 
treated with chemotherapy increased their relapse probability and associated with inferior 
outcomes.91-93  
 
1.7 Measurable residual disease 
Additionally to risk stratification at diagnosis, recently, some studies have shown a strong 
prognostic influence of the presence of measurable residual disease (MRD) in AML at different 
time points during treatment.94-96 There is considerable effort in developing reliable techniques 
to quantify remaining leukemia cells in CR defined by cytomorphological criteria to better predict 
the likelihood of AML relapse. Some study groups cassess MRD by multiparameter flow 
cytometric analysis detection of aberrant surface antigen expression on malignant cells.94 Other 
established methods are quantitative real time polymerase chain reaction (PCR) assays 
detecting disease-specific fusion genes or mutations.95,96 Recent data indicates that the 
detection of genes also expressed in healthy individuals at low levels but upregulated in AML 
patients may further extend MRD evaluation possibilities.96 However, today it remains to be 
determined which molecular markers at which time points and detected by which techniques are 
most suitable for residual disease detection and consequently for AML treatment guidance. 
Currently, this remains a very active field of translational research. 
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2. OWN CONTRIBUTION / EIGENER BEITRAG 
2.1 Purpose and objective of the presented work 
As described above AML is a highly heterogeneous disorder, characterized by the clonal 
expansion of AML progenitors arrested at various stages of myeloid differentiation, and by the 
progressive accumulation of multiple chromosomal, moleculargenetic, and epigenetic 
alterations. Prognosis of patients with AML is strongly influenced by the type of chromosomal 
and moleculargenetic alteration, as well as by aberrant (coding and non-coding) gene 
expression. Today outcomes of most AML patients remain poor. Thus, there is urgent need to 
identify prognostic biomarkers for risk stratification, to identify the underlying AML biology and to 
develop new therapeutic targets to subsequently improve AML patients’ survival. 
The studies included in this habilitation focus on molecular prognostic biomarkers, their clinical 
consequences, how theses markers contribute to a better risk stratification in newly diagnosed 
AML as well as how they may be exploited for MRD assessment and novel treatment 
approaches in AML.  
The frist two paragraphes include publications focusing on recurrent cytogenetic and molecular 
changes and also the aberrant expression of AML associated genes, specifically of BAALC, 
ERG, and MN1, as prognostic markers at AML diagnosis. These studies expanded the 
knowledge on risk stratification in AML and highlighted some of the associated AML-biology. 
The third part shows that AML associated gene expression, i.e. BAALC, also functions as MRD 
marker if measured in complete remission. The fourth part focuses on a differential expression 
of miRs – specifically of miR-181a and miR-29b - as prognostic markers in AML, and reveal 
biological, clinical, and therapeutic implications of the identified aberrant miR expression levels. 
Finally, the included paper in the last paragraph demonstrates that the burden of leukemia 
initiating cells at diagnosis - defined by the bone marrow CD34+/CD38- cell population - impacts 
on outcome in patients undergoing allograft procedures, elucidating the importance of treatment 
approaches targeting leukemia initiating cells.  
 
In summary, twelve publications are included in this work: 
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2.2 Cytogenic aberations and recurrent molecular changes at diagnosis as prognostic 
factors in AML 
The first paper in this paragraph concentrates on the common genetic alteration 
inv(16)(p13q22) / t(16;16)(p13;q22) in AML that results in various CBFB-MYH11 fusion 
transcripts. In AML, the biologic and prognostic implications of different inv(16) fusion-products 
remained unclear. This work analyzed CBFB-MYH11 fusion types in inv(16) / t(16;16) patients 
and found that no patient with non-type A fusion carried a KIT mutation, whereas about a third 
of type A fusion patients did. Among the latter, KIT mutations conferred adverse prognosis. 
Furthermore, non-type A fusions associated with distinct clinical and genetic features and a 
unique gene-expression profile. 
The next study determined the frequency of DNMT3A mutations, their associations with clinical 
and molecular characteristics and outcome, as well as the associated gene- and miR-
expression signatures in CN-AML. Missense mutations affecting arginine codon 882 (R882-
DNMT3A) were more common than those affecting other codons (non-R882-DNMT3A). 
Furthermore, DNMT3A mutations were age dependent: while DNMT3A-R882 mutations were 
associated with adverse prognosis in older AML patients, non-R882-DNMT3A mutations were 
associated with adverse prognosis in younger AML patients.  
The last paper included in this paragraph analyzed the prognostic impact of the 2010 ELN 
genetic groups in AML patients receiving allogeneic HSCT after non-myeloablative conditioning. 
While the prognostic utility of the four ELN 2010 genetic groups (favorable, intermediate-I, 
intermediate-II and adverse) in AML patients consolidated with chemotherapy had already been 
described, their impact after allogeneic HSCT remained to be elucidated. The data presented 
here suggest that the ELN 2010 genetic groups may have a reduced prognostic impact for 
patients undergoing allogeneic HSCT after non-myeloablative conditioning as compared to 
those receiving a chemotherapy-based consolidation in first CR.  
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17 
 
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct 
clinical and genetic features and lack KIT mutations. Blood. 2013; 121:385-91. *shared first-author 
 
- Marcucci G,* Metzeler KH,* Schwind S,* Becker H,* Maharry K, Mrózek K, Radmacher MD, 
Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell B, Carter TH, Kolitz JE, Wetzler M, Carroll 
AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD: Age-related Prognostic Impact of 
Different Types of DNMT3A Mutations in Adults with Primary Cytogenetically Normal Acute Myeloid 
Leukemia. J Clin Oncol. 2012; 30:742-50. *shared first-author 
 
- Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M, Behre G, Vucinic V, Pönisch W, Franke 
GN, Niederwieser D, Schwind S. Prognostic impact of the European LeukemiaNet standardized 
reporting system in older AML patients receiving stem cell transplantation after non-myeloablative 
conditioning. Bone Marrow Transplant. 2017; 52:932-5. 
 
18 
 
19 
 
20 
 
  
21 
 
22 
 
23 
 
  
24 
 
25 
 
  
26 
 
27 
 
  
28 
 
29 
 
  
30 
 
  
31 
 
32 
 
  
33 
 
34 
 
  
35 
 
  
36 
 
  
37 
 
  
38 
 
2.3 Aberrant BAALC, ERG, and MN1 expression at diagnosis as prognostic factors in 
older AML patients 
BAALC, ERG, and MN1 expression levels have been identified as prognostic markers in 
younger (< 60 years) CN-AML adults at diagnosis. However, most AML patients are diagnosed 
aged over 60 years, thus the prognostic impact of BAALC, ERG, and MN1 expression levels in 
older patients required further investigation.  
In the first paper integrated in this paragraph, diagnostic expression levels of BAALC and ERG 
in older AML patients were evaluated. Low BAALC and ERG expression levels were associated 
with better outcome in univariable and multivariable analyses. Expression levels of both BAALC 
and ERG were the only factors significantly associated with OS upon multivariable analysis. 
Furthermore, gene and miR expression signatures associated with BAALC and ERG expression 
were assessed.  
In the second paper included in this paragraph, MN1 expression levels prior to therapy were 
analyzed in older CN-AML patients. Low MN1 expressers had higher CR rates and longer OS 
and event-free survival (EFS). MN1 expresser-status-associated gene- and miR-expression 
signatures revealed underexpression of drug resistance and adverse outcome predictors, and 
overexpression of HOX genes and HOX-gene-embedded miRs in low MN1 expressers.  
Interestingly, similarities in the expression signatures in older AML patients in both papers 
compared to younger patients were revealed, suggesting that the historically evolved 60 years 
might not be the optimal age cut-off regarding biological differences in AML patients. In 
conclusion these two papers expanded the knowledge on the strong prognostic impact of 
BAALC, ERG, and MN1 expression levels in older AML patients and elucidated the associated 
biology by demonstrating gene- and miR-expression signatures. 
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2.4 High BAALC expression as residual disease marker prior to allogeneic stem cell 
transplantation 
Over the last years, assessment of MRD for risk stratification during AML disease course 
became of growing interest. MRD allows the detection of a small residual disease population 
despite morphologic remission. Thus, it has the potential to add valuable prognostic information 
for AML patients and will likely guide treatment decisions in the future. 
The paper included in this paragraph evaluates the feasability of BAALC copy number 
assessment for MRD detection by the novel digital droplet PCR technique, prior to allogeneic 
HSCT in CR. It shows that a BAALC copy number in peripheral blood prior to an allogeneic 
HSCT that is higher than the copy number expressed in a healthy control cohort associates with 
a higher CIR and shorter OS in AML patients. These findings are most likely mediated by 
residual disease cells in patients with high BAALC copy numbers. The paper is the first to 
analyze BAALC as a MRD marker in a patient cohort receiving allogeneic HSCT and shows the 
feasability of MRD assessment independent of a disease-specific molecular alteration. 
 
Manuscripts included in this paragraph: 
 
- Jentzsch M, Bill M, Grimm J, Schulz J, Schubert K, Beinicke S, Häntschel J, Pönisch W, 
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numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute 
myeloid leukemia patients. Oncotarget. 2017. doi: 10.18632/oncotarget.21322 
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ABSTRACT
High BAALC expression levels at acute myeloid leukemia diagnosis have been 
linked to adverse outcomes. Recent data indicate that high BAALC expression levels 
may also be used as marker for residual disease following acute myeloid leukemia 
treatment. Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative 
treatment for acute myeloid leukemia patients. However, disease recurrence remains 
a major clinical challenge and identification of high-risk patients prior to HSCT is 
crucial to improve outcomes. We performed absolute quantification of BAALC copy 
numbers in peripheral blood prior (median 7 days) to HSCT in complete remission (CR) 
or CR with incomplete peripheral recovery in 82 acute myeloid leukemia patients using 
digital droplet PCR (ddPCR) technology. An optimal cut-off of 0.14 BAALC/ABL1 copy 
numbers was determined and applied to define patients with high or low BAALC/ABL1 
copy numbers. High pre-HSCT BAALC/ABL1 copy numbers significantly associated 
with higher cumulative incidence of relapse and shorter overall survival in univariable 
and multivariable models. Patients with high pre-HSCT BAALC/ABL1 copy numbers 
were more likely to experience relapse within 100 days after HSCT. Evaluation of 
pre-HSCT BAALC/ABL1 copy numbers in peripheral blood by ddPCR represents a 
feasible and rapid way to identify acute myeloid leukemia patients at high risk of early 
relapse after HSCT. The prognostic impact was also observed independently of other 
known clinical, genetic, and molecular prognosticators. In the future, prospective 
studies should evaluate whether acute myeloid leukemia patients with high pre-
HSCT BAALC/ABL1 copy numbers benefit from additional treatment before or early 
intervention after HSCT.
INTRODUCTION
The identification of cytogenetic, molecular, and 
clinical factors impacting on outcome at acute myeloid 
leukemia (AML) diagnosis improved risk stratification 
[1, 2]. But pre-treatment AML characterization may 
not capture all parameters important for outcome, e.g. 
response or resistance to therapy [3]. Early detection 
of measurable residual disease (MRD) through 
multiparameter flow cytometric (MFC) or quantitative 
real time PCR (qRT-PCR) assays may allow treatment 
intervention before overt relapse occurs [3–5]. MFC 
enables MRD assessment through detection of aberrant 
surface antigen expression in complete remission (CR) 
[Wormann et al, ASH 1991,6,7]. However, heterogenic 
outcomes were observed in MFC-MRD studies [8] and 
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reproducibility of MFC-MRD assessment is limited by 
the need of specialized laboratories [3, 4]. Sensitive qRT-
PCR enabled MRD detection in AML cases with common 
fusion genes and in NPM1 mutated AML [3, 9, 10]. 
Thus qRT-PCR MRD monitoring is widely restricted to 
patients carrying specific molecular alterations [11] with 
the exception of Wilms' tumor gene 1 (WT1) expression 
[9, 12]. Because clonal evolution can occur at disease 
progression and might complicate early disease detection 
at relapse [13], it seems reasonable to track several MRD 
markers per patient.
The gene brain and acute leukemia, cytoplasmic 
(BAALC) has been suggested as a suitable MRD marker as 
it is expressed at low levels in peripheral blood and bone 
marrow of healthy individuals [14, 15], but upregulated 
in AML patients [15]. High BAALC expression levels 
at AML diagnosis have been shown to associate with 
adverse outcomes [16–19]. Recently, high BAALC levels 
have also been linked to worse outcome if measured by 
qRT-PCR after achievement of CR [15], completion of 
induction therapy [11, 20] or after allogeneic stem cell 
transplantation (HSCT) [21]. However, qRT-PCR has 
the disadvantage of the need of calibration curves and 
poor inter-laboratory comparability. In chronic myeloid 
leukemia (CML) this led to complex harmonization 
efforts for BCR-ABL1 detection [22], which are not yet 
clinical practice for MRD markers in AML. Here we 
adopted digital droplet PCR (ddPCR), a new technique 
which allows an absolute quantification without the need 
of standard curves [23].
Allogeneic HSCT is a potential curative treatment 
option for AML patients and offers the highest chance of 
sustained remissions [2]. Non-myeloablative conditioning 
regimens (NMA), in which the therapeutic success is mainly 
based on graft-versus-leukemia (GvL) effects, enabled 
allogeneic HSCT in comorbid or older individuals [24]. 
Disease recurrence after HSCT remains a major clinical 
problem with short patient survival [25]. Until today, no 
study evaluated the feasibility of BAALC expression levels 
for risk stratification in AML patients prior to allogeneic 
HSCT in CR or CR with incomplete peripheral recovery 
(CRi), which was the main objective of our study. Early 
identification of AML patients at high risk of relapse 
may result in adjustment of treatment strategies prior to 
morphologic relapse and subsequently improve outcomes. 
With the goal of a robust, rapid, and reproducible approach, 
we used peripheral blood to assess the feasibility of ddPCR 
for absolute quantification of BAALC/ABL1 copy numbers.
RESULTS
BAALC/ABL1 copy numbers in AML patients 
prior to HSCT and in healthy individuals
Within the patient cohort in CR or CRi prior to 
HSCT, we observed a median pre-HSCT BAALC/ABL1 
copy number of 0.03 (range 0.00-2.58, Figure 1). In 
the healthy control cohort, median BAALC/ABL1 copy 
numbers were 0.04 (range 0.03-0.10). Overall, there 
was no significant difference in the BAALC/ABL1 copy 
Figure 1: Comparison of absolute BAALC/ABL1 copy numbers in AML patients pre-HSCT (n=82) and healthy 
controls (n=7).
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numbers between both groups (P=.34). The patient cohort 
and the healthy control cohort were evenly matched in age 
(P=1) and sex (P=1, Supplementary Table 2).
Associations of high pre-HSCT BAALC/ABL1 
copy numbers with clinical and biological 
characteristics
Patients with high and low pre-HSCT BAALC/ABL1 
copy numbers did not differ significantly in the evaluated 
characteristics at diagnosis (Table 1, Supplementary Table 1). 
However, there was a trend for a lower incidence of CEBPA 
mutations in patients with high pre-HSCT BAALC/ABL1 
copy numbers (P=.09). Patients with high and low pre-
HSCT BAALC/ABL1 copy numbers also did not differ 
significantly in pre-HSCT characteristics; specifically, no 
significant differences were found regarding the remission 
status at HSCT, white blood count at time of blood sampling 
for BAALC/ABL1 copy number evaluation or time from 
blood sampling to HSCT (Supplementary Table 1).
Prognostic significance of pre-HSCT BAALC/
ABL1 copy numbers
Patients with high pre-HSCT BAALC/ABL1 copy 
numbers had a significantly higher cumulative incidence 
of relapse (CIR, P=.02, Figure 2A) and shorter overall 
survival (OS, P=.03, Figure 2B) which was reproduced 
when we restricted our analysis to patients with a normal 
karyotype (n=38, P=.007 and P=.11, respectively, Figures 
2C and 2D). Subgroup analyses for patients harboring de 
novo disease (n=52, Supplementary Figure 2), patients 
transplanted in CR (n=68, Supplementary Figure 3), 
CD34-positive AML (n=31, Supplementary Figure 4), 
patients surviving longer than 100 days after HSCT 
(n=71, Supplementary Figure 5), as well as patients 
with diagnostic BAALC/ABL1 copy number information 
available (n=51, Supplementary Figure 6) are shown in the 
Supplementary Material.
One year after HSCT, 52% of patients with high pre-
HSCT BAALC/ABL1 copy numbers relapsed compared to 
25% of patients with low pre-HSCT BAALC/ABL1 copy 
numbers. Furthermore, 38% of patients with high pre-
HSCT BAALC/ABL1 copy numbers were alive compared 
to 68% of patients with low pre-HSCT BAALC/ABL1 copy 
numbers. Patients with high pre-HSCT BAALC/ABL1 copy 
numbers suffering relapse had a trend for shorter time 
to relapse after HSCT (median 78, range 19-244 days) 
compared to patients with low pre-HSCT BAALC/ABL1 
copy numbers (median 116, range 27-543 days, P=.07). 
Furthermore, for patients without non-relapse mortality 
after 100 days and six months after HSCT, those with 
high pre-HSCT BAALC/ABL1 copy numbers more 
often relapsed compared to patients with low pre-HSCT 
BAALC/ABL1 copy numbers (37% vs. 11%, P=.02 
[Figure 3], and 73% vs. 27%, P=.002, respectively). In 
multivariable analysis, high pre-HSCT BAALC/ABL1 copy 
numbers significantly associated with higher CIR (Hazard 
Ratio [HR] 2.6, Confidence Interval [CI] 1.2-5.7, P=.01) 
after adjustment for disease status at HSCT (P=.003) and 
disease origin (P=.009) and shorter OS (HR 2.1, CI 1.1-
4.1, P=.03, Table 2).
Detailed comparisons between the four groups of 
patients experiencing relapse or remaining in remission 
with high or low pre-HSCT BAALC/ABL1 copy numbers 
are shown in the Supplementary Material.
DISCUSSION
Assessment of residual disease provides a powerful 
tool to measure treatment responses and to identify 
patients at high risk of relapse [4]. Although we still lack 
data of prospective MRD-guided trials in non-APL (acute 
promyelocyte leukemia) AML, MRD assessment may 
allow preemptive therapy to delay or even prevent relapse 
and improve outcomes [5, 26, 27]. However, about 40% 
of AML patients do not harbor the today commonly used 
molecular MRD targets [3, 4], reflecting a need for new 
MRD markers.
While the prognostic impact of high BAALC 
expression levels at diagnosis has been widely evaluated 
[3, 16–19], only a few studies with limited patient 
numbers evaluated BAALC expression levels during 
disease course using qRT-PCR [11, 15, 20, 21]. For MRD 
evaluation in AML in general, it remains unclear whether 
peripheral blood or bone marrow should be analyzed [7, 
28]. For BAALC, high correlations of expression levels 
in peripheral blood and bone marrow in both newly 
diagnosed AML patients and healthy individuals have 
been shown [15, 16]. While some authors only used 
bone marrow [21], others used BAALC expression levels 
of either blood or bone marrow for survival analysis at 
diagnosis and during disease course [11, 20]. Peripheral 
blood is derived faster, with lower risk of complications 
and a higher convenience for the patient than bone 
marrow aspiration and results in comparable BAALC 
expression data [15, 16]. Therefore, we decided to restrict 
our analysis to peripheral blood samples to examine the 
prognostic impact of absolute pre-HSCT BAALC/ABL1 
copy numbers in patients receiving NMA-HSCT.
None of the aforementioned studies focusing 
on BAALC expression levels during disease course 
reported significant diagnostic clinical or genetic 
associations with different BAALC expression levels 
at a defined point in time in CR. In our study, we also 
did not detect any significant association of high pre-
HSCT BAALC/ABL1 copy numbers with tested pre-
treatment or pre-HSCT parameters. This may indicate 
that the observed higher CIR and subsequent shorter 
OS is indeed driven by residual disease detected by 
high pre-HSCT BAALC/ABL1 copy numbers rather than 
other commonly tested prognostic parameters. The first 
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Table 1: Clinical characteristics of 82 AML patients treated with HSCT according to absolute pre-HSCT 
BAALC/ABL1 copy numbers (high vs. low, 0.14 cut)
Characteristic All patients (n=82)
Low pre-HSCT 
BAALC/ABL1 copy 
numbers (n=61)
High pre-HSCT  
BAALC/ABL1 copy 
numbers (n=21)
P
Pre-HSCT BAALC/ABL1 copy numbers    <.001
 Median 0.03 0.02 0.44  
 Range 0.00-2.58 0.00-0.11 0.14-2.58  
Age at HSCT, years    .79
 Median 63.9 64.9 63.9  
 Range 50.8-76.2 51.5-76.2 50.8-74.9  
Sex, n (%)    .80
 Male 37 27 (44) 10 (48)  
 Female 45 34 (56) 11 (52)  
Hemoglobin at diagnosis, g/dL    .54
 Median 8.7 9.0 8.5  
 Range 4.5-14.4 5.5-14.4 4.5-11.3  
Platelet count at diagnosis, x 109/L    .76
 Median 65 71 63  
 Range 3-224 3-167 13-224  
WBC count at diagnosis, x 109/L    .13
 Median 7.2 4.6 22.4  
 Range 0.7-385 0.8-324 0.7-385  
Blood blasts at diagnosis, %    .48
 Median 22 21 28  
 Range 0-97 0-97 2-97  
BM blasts at diagnosis, %    .87
 Median 50 52 43  
 Range 3-95 3-95 10-95  
Karyotype, n (%)    .45
 Abnormal 41 32 (55) 9 (43)  
 Normal 38 26 (45) 12 (57)  
ELN 2010 Genetic Group, n (%)[36]    .86
 Favorable 17 12 (22) 5 (26)  
 Intermediate-I 19 13 (24) 6 (32)  
 Intermediate-II 19 15 (27) 4 (21)  
 Adverse 19 15 (27) 4 (21)  
Disease origin, n (%)    .60
 De novo 52 40 (66) 12 (57)  
 Secondary 30 21 (34) 9 (43)  
(Continued)
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study to propose BAALC as a potential MRD marker 
analyzed 45 patients with de novo acute leukemia, but 
also included six patients with APL and 11 patients with 
lymphoid leukemia in their analysis [15]. The authors 
were able to show a superior disease-free survival in 
patients with lower BAALC/GAPDH expression levels in 
bone marrow after CR achievement. Another small study 
focused on 45 patients harboring core-binding factor 
(CBF) AML that received an allogeneic or autologous 
HSCT and evaluated BAALC/ABL1 expression levels 
in bone marrow at diagnosis, as well as in CR after the 
first induction cycle, pre-HSCT, and at day 60 post-
HSCT. While the authors showed significantly shorter 
OS, event-free survival (EFS) and higher CIR in patients 
with high BAALC/ABL1 expression levels at diagnosis 
and post-HSCT, there was no significant impact on 
outcome after first induction cycle or pre-HSCT [21]. 
In contrast, we observed a strong prognostic impact of 
high pre-HSCT BAALC/ABL1 copy numbers on CIR 
and OS in univariable and multivariable models. These 
differences might be explained by a lower patient number 
(n=45) and/or the restriction to CBF AML in the study 
of Yoon et al. [21] In 27 CN-AML patients with high 
initial BAALC/ABL1 expression levels, Weber et al. [11] 
observed shorter EFS for individuals with sustained high 
BAALC/ABL1 expression levels in peripheral blood or 
bone marrow after two induction cycles. Later, this data 
was extended to 46 and 33 patients after completion of 
two induction cycles and 3-6 months after completion 
of two induction cycles, respectively [11]. Again, 
patients with high BAALC/ABL1 expression levels 
at either of both time points had shorter EFS. Despite 
this promising data, possible limitations of BAALC as 
MRD marker still have to be determined. While most 
studies showed a prognostic impact without a prior 
assessment of the CD34 expression status [11, 20, 21], 
Najima et al. [15] postulated BAALC as MRD marker 
limited to CD34-positive AML as BAALC is upregulated 
in CD34-positive AML [14]. Restricting our analysis to 
patients with CD34-positive AML, we also observed a 
trend for higher CIR in patients with high pre-HSCT 
BAALC/ABL1 copy numbers despite low patient numbers 
(P=.06, n=31, Supplementary Material). Limited 
numbers of patients with CD34-negative AML prevented 
a separate analysis for this subset. However, we observed 
no difference in CD34-positivity or CD34 expression at 
diagnosis between patients with high or low pre-HSCT 
BAALC/ABL1 copy numbers (Supplementary Table 1). 
Further studies are needed to evaluate whether there are 
specific AML subgroups for which BAALC represents a 
more suitable MRD marker than for others.
To our knowledge until today all studies used qRT-
PCR for BAALC evaluation but different approaches 
to define a cut-off for high or low BAALC expression 
levels during follow-up. Najima et al [15]. used the two-
fold standard deviation over the median of a healthy 
cohort, while Yoon et al. [21] focused on the relative 
BAALC/ABL1 expression of the tested patients and used 
a ROC (receiver operation characteristic) curve to define 
the optimal cut for each point in time individually. The 
Characteristic All patients (n=82)
Low pre-HSCT 
BAALC/ABL1 copy 
numbers (n=61)
High pre-HSCT  
BAALC/ABL1 copy 
numbers (n=21)
P
NPM1 at diagnosis, n (%)    .76
 Wild-type 51 36 (77) 15 (71)  
 Mutated 17 11 (23) 6 (29)  
FLT3-ITD at diagnosis, n (%)    1
 Absent 54 38 (79) 16 (80)  
 Present 14 10 (21) 4 (20)  
CEBPA at diagnosis, n (%)    .09
 Wild-type 51 34 (83) 17 (100)  
 Mutated 7 7 (17) 0 (0)  
ABL1, Abelson murine leukemia viral oncogene homolog 1 gene; BAALC, brain and acute leukemia, cytoplasmatic gene; 
BM, bone marrow; CEBPA, CCAAT/enhancer-binding protein alpha gene; ELN, European LeukemiaNet classification 
2010; FLT3-ITD, internal tandem duplication of the fms like tyrosine kinase 3 gene; HSCT, hematopoietic stem cell 
transplantation; NPM1, nucleophosmin 1 gene; WBC, white blood cell.
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latter resembles our approach and – despite different 
methodology - the evaluated cut-off in our cohort was 
also slightly higher than the two-fold standard deviation 
over the median of healthy BAALC/ABL1 copy numbers 
in peripheral blood (0.14 vs. 0.10, respectively). Finally, 
Weber et al. used the median BAALC/ABL1 expression 
at diagnosis of the initial cohort [11] to define high or 
low expression during disease course but restricted their 
analysis to patients with initially high BAALC/ABL1 
expression levels [11, 20]. In our study, for a subset 
of the analyzed patients (n=51) diagnostic material for 
BAALC/ABL1 copy number assessment was available. 
For patients’ characteristic, as well as clinical and 
biological associations linked with high BAALC/ABL1 
copy numbers at diagnosis see the Supplementary 
Material. When we restricted our outcome analyses to 
patients with low or high BAALC/ABL1 copy numbers 
at diagnosis - despite the limited number of patients 
- we observed a trend for higher CIR and shorter OS 
for patients with high pre-HSCT BAALC/ABL1 copy 
numbers in patients irrespective of the diagnostic 
BAALC/ABL1 copy number (Supplementary Figure 
6). In fact five of the patients with low diagnostic 
BAALC/ABL1 copy numbers had high pre-HSCT 
BAALC/ABL1 copy numbers, of which three 
subsequently relapsed (see Supplementary Material for 
details). Thus, despite the limited number of patients, 
our data indicate that pre-HSCT BAALC/ABL1 copy 
Figure 2: Outcome of patients according to pre-HSCT BAALC/ABL1 copy numbers, high vs low, 0. 14 cut, (A) Cumulative Incidence of 
Relapse and (B) Overall Survival for the entire set (n=82) and (C) Cumulative Incidence of relapse and (D) Overall Survival in patients 
with a normal karyotype (n=38).
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number determination can provide valuable clinical 
information also in patients with low diagnostic 
BAALC/ABL1 copy numbers.
Considering the small number of studies focusing on 
BAALC expression as a MRD marker, the optimal cut-off 
needs validation. However, assessment of BCR-ABL1 as 
MRD marker in CML showed us the technical difficulties 
of standard curves and in achieving an inter-laboratory 
comparability to ensure consistent analyses [22]. ddPCR 
has already been shown to provide comparable sensitivity 
to qRT-PCR but seems to have an improved day-to-day 
reproducibility and greater precision [23, 29, Huang et al, 
ASH 2015]. Therefore, ddPCR may represent a promising 
new method for gene expression analyses for MRD 
monitoring in the future.
Our here presented study is the first to demonstrate 
that ddPCR is a feasible method for evaluation 
of absolute BAALC/ABL1 copy numbers prior to 
allogeneic HSCT. We were able to show that patients 
with high pre-HSCT BAALC/ABL1 copy numbers had 
a significant higher CIR and shorter OS (P=.02 and 
P=.03, respectively, Figure 2). Patients with high pre-
HSCT BAALC/ABL1 copy numbers had an over 2.5-fold 
higher risk of relapse and an over 2-fold higher risk of 
death after HSCT compared to patients with low pre-
HSCT BAALC/ABL1 copy numbers (Table 2). Patients 
with high pre-HSCT BAALC/ABL1 copy numbers 
more often suffered relapse within the first 100 days 
after HSCT (37% vs. 11%, P=.02) and the time from 
HSCT to relapse was shorter in patients with high pre-
HSCT BAALC/ABL1 copy numbers by trend (P=.07, 
Figure 3). To our knowledge, no other study reported 
on early relapses detected by high BAALC expression 
levels. We postulate that high pre-HSCT BAALC/ABL1 
copy numbers might indicate a residual disease burden 
in AML patients that subsequently may lead to early 
relapse during follow-up. Noteworthy, for all patients, 
peripheral blood was used in the analyses facilitating 
repetitive MRD assessment. We and others [11, 15, 20, 
21] were able to show that BAALC has the potential to 
allow further risk stratification during disease course and 
subsequently may improve MRD assessment in addition 
to other established MRD markers such as PML-RARA, 
CBFB-MYH11, RUNX1-RUNX1T1 or NPM1 mutations. 
Furthermore, since BAALC is expressed at different 
amounts in all AML patients, it might allow molecular 
MRD detection in patients lacking molecular alterations 
commonly used for MRD assessment.
Restrictions of our study are the retrospective nature 
and the limited patient numbers. Future prospective 
clinical trials are needed to validate the here-established 
cut-off value and the resulting outcome findings in larger 
patient populations.
Even with a variety of possible treatment options 
such as reduction of immunosuppression, donor 
lymphocyte infusions or treatment with hypomethylating 
agents, patients suffering from morphologic relapse 
after HSCT have a very poor prognosis [25, 30, 31]. 
Pre-HSCT BAALC/ABL1 copy number evaluation 
allows early identification of patients at higher risk of 
relapse and subsequently closer monitoring for relapse 
in the post-transplant period. In the future pre-HSCT 
BAALC/ABL1 evaluation might guide preemptive 
treatment to improve the poor prognosis of AML patients 
with a risk for morphologic relapse. Furthermore, 
prospective studies will be required to evaluate whether 
AML patients with high pre-HSCT BAALC/ABL1 
copy numbers might benefit from additional treatment 
or intensification of the conditioning regimen prior to 
allogeneic HSCT.
Figure 3: Time from HSCT to relapse according to high (median 78, range 19-244 days) or low (median 116, range 
27-543 days) absolute pre-HSCT BAALC/ABL1 copy numbers in relapsed patients (n=28).
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MATERIALS AND METHODS
Patients and treatment
A total of 82 adult AML patients who received 
allogeneic HSCT at the University of Leipzig between 
September 2002 and December 2015 were retrospectively 
included in this analysis. All patients had peripheral blood 
samples up to 14 days prior to HSCT (median 7, range 
0-14 days) for BAALC/ABL1 copy number assessment 
available. White blood count (WBC) was assessed at time 
of blood sampling for analysis. Additionally, for 51 of 
these patients diagnostic peripheral blood or bone marrow 
samples were available for BAALC/ABL1 copy number 
analysis. For details see Supplementary Material and 
Supplementary Table 3.
All patients received age-dependent cytarabine 
based chemotherapy protocols (under or over 60 years) 
and were consolidated with HSCT in first (60%) or 
second CR (23%) or CRi (17%). For details please see 
Supplementary Material. Median age at HSCT was 63.9 
(range 50.8-76.2) years. Written informed consent for 
participation in these studies was obtained in accordance 
with the Declaration of Helsinki.
All patients received NMA conditioning with 
fludarabine 30 mg/m2 for three days followed by 2 Gy 
total body irradiation [32, 33] and infusion of granulocyte 
colony stimulating factor (G-CSF)-mobilized peripheral 
blood stem cells on day 0. Reasons for choosing a NMA 
protocol were age over 50 years for patients receiving 
unrelated HSCT (n=71) or age over 55 years for patients 
receiving related HSCT (n=11). Patients’ characteristics 
are shown in Table 1 and Supplementary Table 1. For 
Information regarding prevention and incidence of acute 
and chronic graft-versus-host disease see Supplementary 
Material. Median follow-up after HSCT for patients alive 
was 1.8 years.
Healthy control cohort
In a control cohort of 7 healthy volunteers (median 
age of 62.7, range 39.6-82.0 years), absolute BAALC/ABL1 
copy numbers in peripheral blood were evaluated. Written 
informed consent was obtained for all healthy individuals; 
their characteristics are shown in Supplementary Table 2.
Cytogenetic, moleculargenetic, and flow 
cytometric analyses
At diagnosis, cytogenetic analyses, the presence 
of internal tandem duplication in the FLT3 gene (FLT3-
ITD) as well as mutations in the FLT3 tyrosine kinase 
domain (FLT3-TKD), NPM1 and CEBPA genes were 
determined as previously described [34]. For details 
see Supplementary Material. For patients with material 
available, the CD34 and CD38 expression on mononuclear 
cells in bone marrow at diagnosis was determined as 
previously described [35].
ddPCR assessment of BAALC/ABL1 copy 
numbers
Absolute BAALC copy numbers were assessed 
using a specific ddPCR assay (BioRad, Hercules, 
Table 2: Multivariable outcome analyses of 82 AML patients treated with HSCT
Variable 
Cumulative Incidence of Relapse Overall survival 
HRa (95% CI) P HRa (95% CI) P
pre-HSCT BAALC/ABL1 copy numbers 
(high vs. low, 0.14 cut) 2.6 (1.2-5.7) .012 2.1 (1.1-4.1) .03
Disease origin (de novo vs. secondary) 0.4 (0.2-0.8) .009 - -
Disease status at HSCT (CR vs. CRi) 0.3 (0.1-0.7) .003 - -
ABL1, Abelson murine leukemia viral oncogene homolog 1 gene; BAALC, brain and acute leukemia, cytoplasmatic gene; 
CI, confidence interval; CR, complete remission; CRi, CR with incomplete peripheral recovery; HSCT, hematopoietic cell 
transplantation; HR, hazard ratio.
a HR, hazard ratio, <1 (>1) indicate lower (higher) risk for an event for the first category listed for the dichotomous 
variables.
Variables considered in the models were those significant at α=0.20 in univariable analyses. For OS endpoint, variables 
considered were hemoglobin count at diagnosis, white blood cell count at diagnosis, pre-HSCT BAALC/ABL1 copy numbers 
(high vs. low) and HLA match (antigen match vs mismatch) while for CIR endpoint, variables considered were disease origin 
(de novo vs. secondary), BAALC/ABL1 copy numbers (high vs. low), disease status at HSCT (CR vs. CRi) and ELN 2010 
Genetic Group.
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California, USA; Assay ID: dHsaCPE5025566) according 
to manufacturer’s specifications. Primers and probe 
sequences for ABL1 copy number assessment (Biomers, 
Ulm, Germany) are shown in the Supplementary Material. 
ddPCR was performed on a QX100 platform (BioRad) 
and QuantaSoft software (Biorad) was used for raw data 
processing. With the droplet generator, each sample was 
divided into approximately 10,000 - 20,000 partitions 
(droplets). After PCR amplification (for details see 
Supplementary Material) the samples were placed into the 
droplet reader, where each droplet was read as positive 
or negative for the gene expression by issuing specific 
fluorescence signals (FAM and HEX). Redistribution 
according to the Poisson’s algorithm determined the target 
copy number in the original sample. Two examples of the 
ddPCR droplet reader output are given in Supplementary 
Figure 1.
BAALC/ABL1 cut-off point definition
Using the R package ‘OptimalCutpoints’ a cut-
off point of 0.1397 absolute pre-HSCT BAALC/ABL1 
copies was determined and used to define patients with 
high (n=21, 26%) and low (n=61, 74%) pre-HSCT 
BAALC/ABL1 copy numbers in peripheral blood. For 
details see Supplementary Material.
End points and statistical analyses
For definition of clinical endpoints and statistical 
analyses for associations and survival (univariable and 
multivariable) see Supplementary Material.
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2.5 Aberrant microRNA expression as prognostic markers in AML and their clinical and 
therapeutic implications 
In recent years it became clearer that differential miR expression levels may not only be used 
for risk stratification but that exploring their biology may provide important insights into AML 
pathogenesis. Furthermore, identifiying ways to manipulate their expression levels may present 
new therapeutic avenues for AML treatment.  
The first part of this paragraph focuses on miR-181a. The first presented paper evaluated the 
prognostic significance of miR-181a expression levels in the context of established molecular 
markers in CN-AML, and aided to gain insight into the leukemogenic role of miR-181a. This 
paper was the first to provide evidence that the expression of a single miR is associated with 
clinical outcome of patients with CN-AML, as higher miR-181a expression associated with 
longer diseas-free survival (DFS) and OS.  
The second paper included in this paragraph demonstrates that high miR-181a expression 
levels lead to a less aggressive AML phenotype by directly downregulating KRAS, NRAS, and 
MAPK1 and decrease AML growth. Furthermore, the paper shows that miR-181a expression 
levels not only represent a strong prognostic marker in AML, but are also involved in AML 
biology by targeting the RAS-MAPK-pathway, and that miR-181a mimics represent a novel 
promising therapeutic approach for AML and possibly for other RAS-driven cancers. 
In the second part of this paragraph the role of miR-29b in AML is characterized and potential 
new treatment strategies are discussed. High expression levels of miR-29b expression 
associated with clinical response to the hypomethylating agent decitabine in older AML patients. 
Bortezomib-induced miR-29b up-regulation resulted in loss of transcriptional activation for 
several genes relevant to AML leukemogenesis. In the third paper a phase 1 trial is presented 
that demonstrates the feasibility and preliminary clinical activity of bortezomib plus decitabine in 
AML, and identified FLT3 as a novel pharmacodynamic end point for future trials.  
In the fourth paper it is demonstrated that the potent histone deacetylase inhibitor AR-42 
increased miR-29b levels and led to downregulation of known miR-29b targets (i.e. SP1, 
DNMT1, DNMT3A and DNMT3B). It also shows that the sequential administration of AR-42 
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followed by decitabine resulted in a strong anti-leukemic activity. These preclinical results with 
AR-42 priming before decitabine administration represent a promising, novel treatment 
approach and a paradigm shift with regard to the combination of epigenetic-targeting 
compounds in AML, where decitabine has been traditionally given before histone deacetylase 
inhibitors. 
In the final paper included in this paragraph it is demonstrated that treatment with a transferrin-
conjugated nanoparticle loaded with synthetic miR-29b (Tf-NP-miR-29b) significantly 
downregulated DNMTs, CDK6, SP1, KIT, and FLT3, decreased AML cell growth and impaired 
colony formation. Mice engrafted with AML cells and then treated with Tf-NP-miR-29b had 
significantly longer survival. Furthermore, priming AML cell with Tf-NP-miR-29b before 
treatment with decitabine resulted in marked decrease in cell viability and showed improved 
antileukemic activity compared with decitabine alone in vivo. 
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2.6 Leukemia Initiating Cell Burden as a prognostic marker in AML 
In AML, leukemia-initiating cells are assumed to exist within the CD34+/CD38- cell 
compartment. These cells are more resistant to chemotherapy, enriched in MRD cell 
populations, and likely responsible for relapse. The here included paper shows that a high 
CD34+/CD38- cell burden at diagnosis independently associated with worse outcome in AML 
patients treated with allogeneic HSCT in CR. The inferior outcome was likely mediated by 
residual leukemia-initiating cells in the bone marrow CD34+/CD38- cell population, escaping the 
graft versus leukemia effects after allogeneic HSCT. The paper was the first to analyse the 
prognostic impact of a leukemia-initiating cell population in AML patients consolidated with an 
allogeneic HSCT and demonstrated the feasibility of the CD34+/CD38- cell burden as a marker 
for risk stratification and a potential therapeutic target.  
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Niederwieser D, Schwind S. Prognostic impact of the bone marrow CD34+/CD38- cell burden at 
diagnosis in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. Am J 
Hematol. 2017; 92:388-96. 
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3. CONCLUSUION and FUTURE PERSPECTIVES / ZUSAMMENFASSUNG und AUSBLICK 
3.1 Conclusion: molecular characteristics in AML 
The publications discussed in the here presented work on molecular biomarkers have 
contributed to a better understanding of leukemogenic pathways, let to improved risk 
assessment and demonstrated possible novel treatment strategies in AML. Besides the 
importance for translational and functional research in the presense and future improved 
molecular characterisation of AML patients has the potential to adjust risk assessment at 
diagnosis or during disease course as demonstrated in multiple examples in this work. Some 
molecular markers have already been integrated in today’s risk stratification which underlines 
the importance of these findings. Apart from coding genes and proteins, miRs may function as 
targets for new treatment approaches, e.g. by upregulation/ downregulation following 
sequenical treatment prior to cytotoxic therapy. Promising data is provided in animal studies and 
early clinical phase trials in examples in this work. Furthermore, the burden of leukemia initiating 
cells has been shown to provide high prognostic significance and can also contribute to risk 
assessment, highlighting athe importance of clinically evaluating therapeutic approaches to 
tartget this cell population. 
 
3.2 Clonal evolution 
Even though substantial advancements have been achieved in understanding AML biology - 
that also led to the development of novel targeted therapies - and patients’ risk stratification has 
continuously been improved, outcomes for most AML patients’ remain unsatisfactory. Novel 
methodologies, such as next-generation-sequencing to explore moleculargenetic and epigenetic 
changes that drive AML leukemogenesis are beeing implemented and help to understand this 
clinically and genetically very heterogeneous disease.  
In the last years substantial effort has been put into further understanding pre-AML conditions 
and the definition of pre-leukemic stages has evolved.97-99 Patients diagnosed with 
myelodysplastic syndrome, individuals with germline mutations in certain transcription factors 
(such as RUNX1 or CEBPA), or with preceding therapies for unrelated neoplasms such as 
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alkylating chemotherapy or radiation show an elevated risk to develop AML.97,98,100 Apart form 
these conditions, recently it was noted that some mutations found in AML patients (e.g. in the 
DNMT3A, TET2, IDH1 or IDH2 gene) can also be found in older 'healthy' individuals who have 
an increased risk of developing frank AML.99,101,102 In ‘healthy’ individuals these mutations have 
been linked to cloncal hematopoiesis, and the term ‘clonal hematopoiesis of indeterminate 
potential’ (CHIP) was coined, indicating a pre-leukemic condition similar to monoclonal 
gammopathy of undetermined significance (MGUS) or monoclonal B-cell lymphocytosis (MBL). 
Understanding the connection of these mutations linked to the phenomenon of clonal 
hematopoiesis, AML and the impact on prognosis and treatment may provide important 
information to improve patients’ outcomes in the future and today represents an active field of 
research. 
 
3.3 Further defining the leukemia initiating cell population 
Since AML is thought to be initiated and maintained by a population of leukemia initiating cells, 
in the past years growing efforts have been put into identifying the phenotype (e.g. the 
CD34+/CD38- subpopulation84 or expression of the G protein-coupled receptor 56 [GPR56]103) 
of these cells. Additionally, there is increasing evidence that a high expression of stem cell gene 
signatures is associated with poor clinical outcomes.104,105 Since also the diagnostic burden of 
these cells has been associated with outcome it seems crucial to identifiy and target this 
populations to improve remission rates and long term survival for AML patients. Additionally, 
better characterisation of the leukemia initiating cell phenotyp may improve methods for MRD 
assessment, since it may allow for a more sensitive and clinical significant detection of 
remaining disease burden during or after AML treatment. 	
 
These recent developments are examples of current focuses in the field of translational AML 
research that may in the future be able to further improve AML risk stratifications, treatment, and 
outcomes.  
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5. INDEX OF ABREVIATIONS / ABKÜRZUNGSVERZEICHNIS 
 
A 
AML    acute myeloid leukemia 
APL   acute promyelocytic leukemia 
ASXL1   additional sex combs like 1  
ATRA   all-trans retinoid acid 
 
B 
BAALC   brain and acute leukemia, cytoplasmic  
 
C 
CBF   core-binding factor 
CD   cluster of differentiation 
CDK6   cyclin dependent kinase 6 gene 
CEBPA / C/EBPα CCAAT/enhancer-binding protein alpha gene / protein 
CHIP   clonal hematopoiesis of indeterminate potential 
CIR   cumulative incidence of relapse 
CN-AML   normal cytogenetics 
CR   complete remission 
 
D 
DFS   disease-free survival  
DNMT   DNA methyltransferase  
 
E 
EFS   event-free survival 
ELN   European LeukemiaNet 
ERG   ETS-related gene 
ETV6   translocation-Ets-leukemia virus 
 
F 
FAB   French American British 
FLT3-ITD  internal tandem duplikation in the Fms related tyrosine kinase 3 gene 
FLT3-TKD  tyrosine kinase domain of the Fms related tyrosine kinase 3 
 
G 
GvL   graft versus leukemia 
GPR56   G protein-coupled receptor 56   
 
H 
HSCs   hematopoietic stem cells 
HSCT   hematopoietic stem cell transplantation 
HOX   homebox 
 
I 
IDH   isocitrate dehydrogenase 
 
K 
KRAS   kirsten rat sarcoma 
 
M 
MAPK   mitogen-activated protein kinase 
MPL   monoclonal B-cell lymphocytosis 
MGUS   monoclonal gammopa 
miR   microRNA 
MN1   meningeoma-1 
MHY11   myosin heavy chain 11 
MRD   measurable residual disease 
 
N 
NPM1   nucleophosmin-1 
NRAS   neuroblastoma rat sarcoma 
 
O 
OS   overall survival 
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R 
RAS   rat sarcoma 
RUNX1   Runt-related transcription factor 1 
 
S 
SP1   specificity protein 1 
 
T 
TP53   tumor protein 53 
 
W 
WHO   World Health Organisation 
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6. Eidesstattliche Erklärung zur vorgelegten Habilitationsschrift 
 
Hiermit erkläre ich an Eides statt,  
1. dass die vorliegende Habilitationsordnung der Medizinischen Fakultät der Universität 
Leipzig anerkannt wird; 
2. dass die Habilitationsschrift in dieser oder ähnlicher Form an keiner anderen Stelle zum 
Zweck eines Graduierungsverfahrens vorgelegt wurde; 
3. dass die Habilitationsschrift selbstständig verfasst und keine anderen als die angegebenen 
Quellen und Hilfsmittel benutzt wurden; 
4. dass die Einhaltung der Satzung der Universität Leipzig zur Sicherung guter 
wissenschaftlicher Praxis“ in der Erstfassung vom 17. April 2015 Grundlage der 
Forschungstätigkeit war. 
 
 
 
 
Dr. med. Sebastian Schwind 
Leipzig, 10.10.2017  						
145 
 
8. COMPLETE LIST OF PUBLICATIONS 
 
Peer-Reviewed Publications 
 
1 Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CEA, Callegari E, Schwind S, Pang J, Yu J, Natarajan MN, 
Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield C.D, Byrd JC, Chan K, 
Wu LC, Croce CM, Marcucci G: MicroRNA-29b induces global DNA hypomethylation and tumor 
suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and 
indirectly DNMT1. Blood. 2009; 113:6411-8. 
 
2 Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu Y, 
Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri 
MA, Larson RA, Bloomfield CD: Favorable prognostic impact of NPM1 mutations in older patients with 
cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-
expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28:596-604. 
 
3 Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, 
Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, 
Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D: miR-328 
functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. 
Cell. 2010; 140:652-65. 
 
4 Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, 
Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever 
MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G: Clinical response and miR-29b predictive 
significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U 
S A. 2010; 107:7473-8. 
 
5 Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, 
Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, 
Caligiuri MA, Larson RA, Bloomfield CD: IDH1 and IDH2 gene mutations identify novel molecular 
subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group 
B study. J Clin Oncol. 2010; 28:2348-55. 
 
6 Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, 
Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan 
KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G: 
Sp1/NFkappaB /HDAC /miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 
2010; 17:333-47. 
 
7 Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, 
Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, 
Moore JO, Caligiuri MA, Larson RA, Bloomfield CD: Mutations of the Wilms tumor 1 gene (WT1) in 
older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia 
Group B study. Blood. 2010; 116:788-92. 
 
8 Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, 
Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, 
Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: FLT3 internal tandem 
duplication associates with adverse outcome and gene- and microRNA-expression signatures in 
patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a 
Cancer and Leukemia Group B study. Blood. 2010; 116:3622-6. 
 
9  Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, 
Whitman SP, Wu Y, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, 
Caligiuri MA, Larson RA, Bloomfield CD: BAALC and ERG expression levels are associated with 
outcome and distinct gene- and microRNA-expression profiles in older patients with de novo 
cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood. 2010; 
116:5660-9.  
 
146 
 
10  Schlaak M*, Schwind S*, Wetzig T, Maschke J, Treudler R, Basara N, Lange T, Simon JC, 
Niederwieser  D, Al-Ali HK: Ultaviolet A (UVA-1) in acute graft- versus- host disease of the skin. Bone 
Marrow Transplant. 2010; 45:141-8. *shared first-author 
 
11  Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, 
Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, 
Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD: Prognostic Significance of Expression of a Single 
microRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia 
Group B Study. J Clin Oncol. 2010; 28:5257-64. 
 
12 Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, 
Schwind S, Whitman SP, Wu Y, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer 
MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: TET2 mutations refine the new 
European LeukemiaNet (ELN) risk classification of adult primary cytogenetically normal acute myeloid 
leukemia: A Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29:1373-81. 
 
13 Becker H, Maharry K, Radmacher MD, Mrózek K, Metzeler KH, Whitman SP, Schwind S, 
Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, 
Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD: Clinical outcome and gene- and microRNA-
expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in 
adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 
Haematologica. 2011; 96:1488-95. 
 
14 Schwind S*, Marcucci G*, Kohlschmidt J,  Radmacher MD, Mrózek K, Maharry K, Becker H, Metzeler 
KH, Whitman SP, Wu Y, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA, Caligiuri MA, Bloomfield 
CD: Low expression of MN1 associates with better treatment response in older patients with de novo 
cytogenetically normal acute myeloid leukemia. Blood. 2011; 118:188-98. *shared first-author 
 
15 Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman 
SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, 
Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: ASXL1 Mutations Identify a High-Risk Subgroup 
Of Older Patients with Primary Cytogenetically Normal AML Within the ELN ‘Favorable’ Genetic 
Category. Blood. 2011; 118:6920-9. 
 
16 Rodriguez B, Tam HH, Frankhouser D, Trimarchi M, Murphy M, Kuo C, Parikh D, Ball B, Schwind S, 
Curfman J, Blum W, Marcucci G, Yan P, Bundschuh R. A Scalable, Flexible Workflow for MethylCap-
Seq Data Analysis.IEEE Int Workshop Genomic Signal Process Stat. 2011:1-4. 
 
17 Marcucci G*, Metzeler KH*, Schwind S*, Becker H*, Maharry K, Mrózek K, Radmacher MD, 
Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell B, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, 
Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD: Age-related Prognostic Impact of 
Different Types of DNMT3A Mutations in Adults with Primary Cytogenetically Normal Acute Myeloid 
Leukemia. J Clin Oncol. 2012; 30:742-50. *shared first-author 
 
18 Whitman S, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrózek K, Wu YZ, 
Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, 
Carroll AJ, Larson RA, Marcucci G, Bloomfield CD: The MLL partial tandem duplication in adults aged 
60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia. 2012; 
26:1713-7. 
 
19 Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, 
Radmacher MD, Bloomfield CD, Tanner SM, de la Chapelle A: Heritable polymorphism predisposes to 
high BAALC expression in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2012; 109:6668-73. 
 
20 Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, 
Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Baer MR, Powell B, Carter T, Moore JO, Kolitz JE, 
Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD: miR-3151 
interplays with its host gene BAALC and independently impacts on outcome of patients with 
cytogenetically normal acute myeloid leukemia. Blood. 2012; 120:249-58.    
 
147 
 
21 Blum W*, Schwind S*, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, 
Santhanam R, Wang H, Curfman JP, Jacob S, Caligiuri M, Chan K, Garr C, Kefauver C, Grever M, 
Perrotti D, Byrd J, Bloomfield CD, Garzon R, Marcucci G. Clinical and Pharmacodynamic Activity of 
the Combination Bortezomib and Decitabine: a Phase I Trial in Patients with Acute Myeloid Leukemia 
(AML). Blood. 2012; 119:6025-31. *shared first-author 
 
22 Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, 
Jihane K, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, 
Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: RUNX1 Mutations Associate with 
Poor Outcome in Younger and Older Patients with Cytogenetically Normal Acute Myeloid Leukemia 
and with Distinct Gene- and MicroRNA-Expression Signatures. J Clin Oncol. 2012; 30:3109-18.   
 
23 Mrózek K, Marcucci G, Nicolet D, Maharry K, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu 
YZ, Kohlschmidt J, Pettenati MJ, Heerema NA, Block AMW, Patil SR, Baer MR, Kolitz JE, Moore JO, 
Carroll AJ, Stone RM, Caligiuri MA, Bloomfield CD: Prognostic Significance of the European 
LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Acute 
Myeloid Leukemia: a Study of 1,550 Adults With Primary Disease. J Clin Oncol. 2012; 30:4515-23. 
 
24 Mims A, Walker A, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, 
Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, Lee LJ, Jacob S, 
Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S,* Marcucci G*: Increased anti-leukemic 
activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting 
approach in acute myeloid leukemia; Leukemia. 2013; 27:871-8. *shared senior-author 
 
25 Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Houda A, 
Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, 
Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, 
Marcucci G: Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein upregulates 
expression of the anti-leukemic microRNA-181a in acute myeloid leukemia. Blood. 2013; 121:159-69. 
 
26 Schwind S,* Edwards CG,* Nicolet D, Mrózek K, Maharry K, Wu YZ, Paschka P, Eisfeld AK, 
Hoellerbauer P,Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, 
Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Volinia S, Marcucci G, Bloomfield CD: 
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct 
clinical and genetic features and lack KIT mutations. Blood. 2013; 121:385-91. *shared first-author 
 
27 Rodriguez BA, Frankhouser D, Murphy M, Trimarchi M, Tam HH, Curfman J, Huang R, Chan MW, Lai 
HC, Parikh D, Ball B, Schwind S, Blum W, Marcucci G, Yan P, Bundschuh R: Methods for high-
throughput MethylCap-Seq data analysis. 2012; BMC Genomics, Oct 26;13 Suppl 6:S14. 
 
28 Wang H, Chen P, Wang X, Santhanam R, Wu J, Saradhi V, Liu X, Schwind S, Mims A, Byrd J, 
Grever M, Villalona M, Klisovic R, Walker A, Garzon R, Blum W, Chan S, Marucci G: In vivo 
Quantification of Active Decitabine-Triphosphate Metabolite: a Novel Pharmacoanalytical Endpoint for 
Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia. The AAPS Journal. 2013; 
15:242-9. 
 
29 Phillips CL, M Davies SM, McMasters R, Absalon M, O’Brien M, Mo J, Broun R, Moscow JA, Smolarek 
T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JP: Low Dose Decitabine in Very High 
Risk Relapsed or Refractory Acute Myeloid Leukemia in Children and Young Adults. Br J Haematol. 
2013; 161:406-10. 
 
30 Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschimdt J, 
Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll A, Powell B, Kolitz JE, Garzon R, 
Caligiuri M, Stone RM, Bloomfield CD: The Clinical Role of microRNAs in Cytogenetically Normal 
Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients. J Clin 
Oncol. 2013; 31:2086-93. 
 
31 Huang X,* Schwind S,* Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker A, 
Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy 
N, Lee LJ, Marcucci G: Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic 
148 
 
Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia. Clin Canc Res. 
2013; 19:2355-67. *shared first-author 
 
32 Mendler JH, Maharry KH, Becker B, Eisfeld AK, Senter L, Mrozek K, Kohlschmidt J, Metzeler KH, 
Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, Marcucci G, CD 
Bloomfield: In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, 
RUNX1 mutations are unusual in structure and present in the germline. Haematologica. 2013;98:e92-
4. 
 
33 Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, Nicolet D, Whitman SP,  
Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Bayard L. Powell BL, Carter TH, Wetzler M, Kolitz JE, 
Baer MR, Carroll AJ; Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD: A stem cell-like gene 
expression signature associates with a distinct microRNA expression profile and inferior survival in 
adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013; 27:2023-31. 
 
34 Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu 
YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll 
AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, 
Stone RM, Volinia S, Bundschuh R, Bloomfield CD: Epigenetics Meets Genetics in Acute Myeloid 
Leukemia: Clinical Impact of a Novel Seven Gene Score. J Clin Oncol. 2014; 32:548-56. 
 
35 Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Nicolet D, Schwind S, Becker H, 
Metzeler HK, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, 
Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD. GAS6 expression identifies high-risk adult AML 
patients: implications for therapy. Leukemia. 2014; 28:1252-8. 
 
36 Eisfeld AK*, Schwind S*, Hoag K, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan 
W, Otterson GA, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. NRAS isoforms 
differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S 
A. 2014; 111:4179-84. *shared first-author 
 
37 Becker H, Maharry K, Mrózek K, Volinia S, Radmacher MD, Eisfeld AK, Kohlschmidt J, Metzeler KH, 
Schwind S, Whitman SP, Mendler JH, Wu YZ, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz 
JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CD. Prognostic gene 
mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a 
sole trisomy 8. Leukemia. 2014; 28:1754-8 
 
38 Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Jarvinen TM, Leffel 
B, Perrotti D, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. Intronic miR-3151 drives 
leukemogenesis by direct deregulation of TP53 and explains the impact of the miR-3151/BAALC locus 
in acute myeloid leukemia. Sci Signal. 2014; 7(321):ra36  
 
39 Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler HK, Eisfeld AK, Maharry K, Yan P, 
Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer 
MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Stone RM, Krzysztof M, Bloomfield 
CD. High DNMT3B Expression Associates with Adverse Outcome in Older Cytogenetically Normal 
Patients with Primary Acute Myeloid Leukemia. 2015; Leukemia. 29:567-75. 
 
40 Zhao X, Huang X, Wang X, Wu Y, Eisfeld AK, Schwind S, Gallego-Perez D, Boukany PE, Marcucci 
G, Lee J. Nanochannel Electroporation as a Platform for Living Cell Interrogation in Acute Myeloid 
Leukemia. Adv Sci. 2015; 2: 1500111. 
 
41 Poenisch W, Plötze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, 
Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, 
Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, Al-Ali 
HK, Niederwieser D. Stem cell mobilization and autologous stem cell transplantation after 
pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple 
myeloma. J Cancer Res Clin Oncol. 2015; 141:2013-22. 
 
42 Pfrepper C, Klink A, Behre G, Schenk T, Franke G-N, Jentzsch M, Schwind S, Al-Ali H-K, Hochhaus 
A, Niederwieser D, Sayer HG.	Risk factors for outcome in refractory acute myeloid leukemia patients 
149 
 
treated with a combination of fludarabine, cytarabine and amsacrine followed by a reduced intensity 
conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol. 2016; 142:317-24. 
 
43 Huang X*, Schwind S*, Santhanam R, Eisfeld AK, Chiang C, Yu B, Hoellerbauer P, Dorrance A, Jin 
Y, Tarighat SS, Khalife J, Walker A, Chan KK, Caligiuri M, Perrotti D, Muthusamy N, Bloomfield CD, 
Garzon R, Lee RJ, Lee JL, Marcucci G. Targeting the RAS/MAPK pathway with miR-181a in Acute 
Myeloid Leukemia. Oncotarget.	2016;	7:59273-86.	*shared first-author 
 
44 Eisfeld AK, Kohlschmidt J, Schwind S, Nicolet D, Blachly JS, Orwick S, Shah C, Bainazar M, Kroll K, 
Walker CJ, Carroll AJ, Powell BL, Stone RM, Kolitz JE, Baer MR, de la Chapelle A, Mrózek K, Byrd 
JC, Bloomfield CD. Novel mutations in the CCND1 and CCND2 genes are frequent events in adult 
patients with acute myeloid leukemia and t(8;21)(q22;q22): CALGB 8461, 9665, and 20202 (Alliance). 
Leukemia.	2017; 31:1278-85. 
 
45 Jentzsch M, Bill M, Leiblein S, Schubert K, Pleß M, Bergmann U, Wildenberger K, Schuhmann L, 
Cross M, Pönisch W, Franke GN, Vucinic V, Lange T, Behre G, Mrózek K, Bloomfield CD, 
Niederwieser D, Schwind S. Prognostic impact of the bone marrow CD34+/CD38- cell burden at 
diagnosis in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. Am J 
Hematol. 2017; 92:388-96. 
 
46 Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M, Behre G, Vucinic V, Pönisch W, Franke 
GN, Niederwieser D, Schwind S. Prognostic impact of the European LeukemiaNet standardized 
reporting system in older AML patients receiving stem cell transplantation after non-myeloablative 
conditioning. Bone Marrow Transplant. 2017;52:932-5. 
 
47 Henker R, Schwind S, Döhring C, Heindl M, Beimer M, Hoffmeister A, Karlas T. Giant duodenal 
hematoma after duodenal biobsy in a patient with suspected acute gastrointestinal graft-versus-host 
disease. 2017; Endoscopy. 49(S 01):E132-133. 
 
48 Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker 
C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, 
Niederwieser D, Poenisch W. Successeful Treatment of Patients with newly diagnosed/untreated light 
chain Multiple Myeloma with a Combination of Bendamustine, Prednisone and Bortezomib (BPV). 
2017; J Cancer Res Clin Oncol. doi: 10.1007/s00432-017-2439-x. 
 
49 Dias A, Al-Kali A, Van Dyke D, Niederwieser D, Vucinic V, Muller C, Schwind S, Teichmann AC, 
Bakken R, Burns LJ, Litzow M. Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic 
Cell Transplant Recipient Representative of a Donor Derived Constitutional Abnormality. 2017; Biol 
Blood Marrow Transplant. pii: S1083-8791(17)30466-4. 
 
50 Wurm AA, Zjablovskaja P, Kardosova M, Gerloff D, Bräuer-Hartmann D, Katzerke C, Hartmann JU, 
Benoukraf T, Fricke S, Hilger N, Müller AM, Bill M, Schwind S, Tenen DG, Niederwieser D, Alberich-
Jorda M, Behre G. Disruption of the C/EPAα-miR-182 balance impairs granulocytic differentiation. Nat 
Commun. 2017;8:46. 
 
51 Beck J, Schwarzer A, Gläser D, Mügge LO, Uhlig J, Heyn S, Kragl B, Mohren M, Hoffmann FA, Lange 
T, Schliwa T, Zehrfeld T, Becker C, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Bill M, 
Jentzsch M, Schwind S, Niederwieser D, Pönisch W. Lenalidomid in combination with bendamustine 
and prednisolon in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-
#077). 2017; J Cancer Res Clin Oncol. Doi: 10.1007/s00432-017-2504-5. Epub ahead of print. 
 
52 Jentzsch M, Bill M, Grimm J, Schulz J, Schubert K, Beinicke S, Häntschel J, Pönisch W, Franke GN, 
Vucinic V, Behre G, Lange T, Niederwieser D, Schwind S. High BAALC copy numbers in peripheral 
blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. 
Oncotarget. 2017. doi: 10.18632/oncotarget.21322. Epub ahead of print 
 
53 Namasu CY, Katzerke C, Bräuer-Hartmann D, Wurm AA, Hartmann JU, Schwind S, Müller-Tidow C, 
Hilder N, Fricke S, Christopeit M, Niederwieser D, Behre G. ABR, a novel inducer of transcription 
factor C/EPAα, contributes to myeloid differentiation and is a favorable prognostic factor in acute 
myeloid leukemia. 2017; Oncotarget. Accepted for publication. 
 
150 
 
 
Conference Proceedings und Abstracts 
 
1 Al-Ali HK, Schwind S, Becker C, Mueller C, Niederwieser D: 5-Azacitidine Induces Hematologic 
Responses in a High Proportion of Patients with Acute Myeloid Leukaemia Refractory to or Not 
Eligible for Intensive Chemotherapy. Blood. 108:552A-552A (Abstract #1953) 2006. 
 
2 Al-Ali HK, Schwind S, Becker C, Mueller C, Niederwieser D: 5-Azacitidine in patients with acute 
myeloid leukemia refractory to or not eligible for intensive chemotherapy and transfusion dependent 
myeloproliferative diseases. Onkologie. 29(S3):92-92 (Abstract #P479) 2006.  
 
3 Al-Ali HK, Schwind S, Krahl R, Becker C, Leiblein S, Mueller C, Niederwieser D: Epigenetic Therapy 
with 5-Azacitidine In A Treatment Schedule Of  Five Days Repeated Every 4 Weeks Can Induce 
Hematologic Responses In Patients With Acute Myeloid Leukaemia Refractory To Or Not Eligible For 
Intensive Chemotherapy. Haematologica. 92(S1): 7-7 (Abstract #0019) 2007. 
 
4 Al-Ali HK, Schwind S, Becker C, Mueller C, Niederwieser D: Safety and Efficancy of 5-Azacitidine for 
five days every 4 weeks in patients with Acute Myeloid Leukaemia (AML) refractory to or not eligible 
for intensive Chemotherapy. Onkologie. 30(S3):186-187 (Abstract #P697) 2007. 
 
5 Schwind S, Lange T, Basara N, Niederwieser D, Al-Ali HK: Allogeneic Hematopoietic Cell 
Transplantation (HCT) for Ph+ Chronic Myeloid Leukaemia (CML) in Second Chronic Phase after 
Treatment with the New Tyrosine Kinase Inhibitor Dasatinib is Feasible and may lead to Complete 
Molecular Responses. Onkologie. 30(S3):202 (Abstract #P746) 2007. 
 
6 Schwind S, Marcucci G, Maharry K, Radmacher MD, Whitman SP, Paschka P, Mrózek K, Kolitz JE, 
Larson RA, Bloomfield CD: MicroRNA-181a expression as a prognosticator in cytogenetically normal 
acute myeloid leukemia (CN-AML). J Clin Oncol. 27:15s (Abstract #7001) 2009. 
 
7 Schwind S, Marcucci G, Maharry K, Mrózek K, Radmacher MD, Holland KB, Becker H, Whitman SP,  
Wu Y, Baer MR, Powell BL, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD: Aberrant Gene 
Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute 
Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study. Blood. 114:93-94 
(Abstract #214) 2009. 
 
8 Whitman SP, Maharry K, Radmacher MD, Mrózek K, Margeson D, Holland KB, Becker H, Wu Y, 
Schwind S, Baer MR, Powell BL, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, 
Bloomfield CD: Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-
Associated in Older [ 60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-
AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. Blood. 114:631-632 (Abstract 
#1579) 2009. 
 
9  Hickey C, Schwind S, Becker H, Alachkar H, Garzon R, Wu Y, Liu S, Perrotti D, Marcucci G: 
MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute 
Lymphocytic Leukemia (ALL) Cells. Blood. 114:318-318 (Abstract #766) 2009. 
 
10 Chandler JC, Klisovic RB, Phelps MA, Walker A, Garzon R, Yang X, Schaaf L, Schwind S, Becker H, 
Liu S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W: Phase I 
Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid 
Leukemia. Blood. 114:346-347 (Abstract #841) 2009. 
 
11  Eiring AM, Harb J, Neviani P, Oaks J, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker 
H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner C, Bhatia R, Roy D, Liebhaber S, Caligiuri 
MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D: Suppression of RISC-Independent Decoy 
and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-
Arrest and Enhanced Survival of Blast Crisis CML Progenitors. Blood. 114:351-352 (Abstract #855) 
2009. 
 
12  Liu S, Lai CW, Pang J, Santhanam R, Schwind S, Wu Y, Hickey C, Yu J, Mishra A, Becker H, Li C, 
Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, Byrd JC, Perrotti D, Garzon R, Marcucci G: 
Evidence of MicroRNA-29b and Sp1/NFkappaB-HDAC Regulatory Network for KIT Expression in KIT-
151 
 
Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications. Blood. 114:387-387 
(Abstract #938) 2009. 
 
13 Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Whitman SP, Paschka P, Margeson D, 
Wu Y, Schwind S, Langer C, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: 
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older ( 60 
years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute 
Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study. Blood. 114:138-138 
(Abstract #326) 2009. 
 
14 Schwind S, Marcucci G, Holland KB, Mrózek K, Radmacher MD, Maharry K, Becker H, Whitman SP, 
Wu Y, Carter TH, Powell BL, Caligiuri MA, Baer MR, Larson RA, Bloomfield CD: Higher MN1 
Expression is an Unfavorable Prognosticator in Older Patients (Pts) with Cytogenetically Normal Acute 
Myeloid Leukemia (CN-AML). Cancer Research. 70 (Abstract #2717) 2011. 
 
15 Alachkar H, Liu S, Schwind S, Becker H, Metzeler KH, Hickey C, Pang J, Whitman SP, Chan KK, 
Garzon R, Lucas DM, Perrotti D, Wu LC, Grever MR, Kinghorn AD, Marcucci G: The natural product 
silvestrol decreases oncogenic FLT3 and miR-155 levels in FLT3-ITD positive Acute Myeloid 
Leukemia (AML). Cancer Research. 70 (Abstract #3558) 2011. 
 
16 Eiring AM, Harb J, Neviani P, Oaks J, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker 
H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner C, Bhatia R, Roy D, Liebhaber S, Caligiuri 
MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D: Suppression of RISC-Independent Decoy 
and RISC-Mediated RNA-Pairing Activities of MicroRNA-328 Is Required for Maturation-Arrest and 
Enhanced Survival of Blast Crisis CML Progenitors. Cancer Research. 70 (Abstract #1950) 2011.  
 
17 Blum W, Klisovic RB, Garzon R, Walker A, Schwind S, Liu SJ, Schaaf L, Garr C, Devine SM, Grever 
MR, Byrd JC, Marcucci G: Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid 
Leukemia (AML). Blood 116:1349-1349 (Abstract #3293) 2010. 
 
18 Covey TM, Gulrajani M, Becker H, Chandler JC, Schwind S, Marcucci G, Cesano A: Single Cell 
Network Profiling as a Platform to Reveal Leukemia-Specific Signaling Signatures and Sensitivity to 
Kinase Inhibitor Therapies. Blood 116:1135-1135 (Abstract #2753) 2010. 
 
19 Becker H, Maharry K, Radmacher MD, Margeson D, Mrozek K, Whitman SP, Wu Y, Metzeler KH, 
Schwind S, Holland KB, Kolitz JE, Carroll A, Caligiuri M, Baer M, Larson RA, Marcucci G, Bloomfield 
CD: Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with 
Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and 
Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study. Blood 116:255-255 
(Abstract #577) 2010. 
 
20 Mishra, A, Liu, SJ, Sams, GH, Curphey, DP, Santhanam, R, Rush, LJ, Schaefer, D, Falkenberg, LG, 
Sullivan, L, Jaroncyk, L, Zou, XC, Fisk, H, Labanowska, J, Caserta E, Wu LC, Becker H, Schwind S, 
Chandler JC, Wu, YZ, Heerema, NA, Porcu, P, Garzon, R, Marcucci, G, Caligiuri, MA: Interleukin-15 Is 
a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia. Blood 116:311-311 (Abstract 
#704) 2010. 
 
21 Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, 
Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, 
Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: Mutations In the Tet 
Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification 
of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and 
Leukemia Group B (CALGB) Study. Blood 118:48-49 (Abstract #98) 2010. 
 
22 Marcucci G, Maharry K, Wu Y, Radmacher MD, Mrózek K, Margeson D, Holland K, Whitman SP, 
Becker H, Schwind S, Metzeler KH, Powell B, Carter T, Kolitz J, Wetzler M, Baer M, Carroll A, 
Caligiuri M, Larson RA, Bloomfield CD: IDH1 and IDH2 gene mutations identify novel molecular 
subsets within de novo cytogenetically normal Acute Myeloid Leukemia (CN-AML): A Cancer and 
Leukemia Group B (CALGB) Study. Haematologica. 95(S2):456-456 (Abstract #1107) 2010. 
 
152 
 
23 Metzeler KH, Maharry K, Margeson D, Curfman J, Becker H, Radmacher MD, Mrózek K, Holland K, 
Whitman SP, Wu Y, Schwind S, Blum W, Powell B, Carter T, Baer M, Carroll A, Kolitz J, Caligiuri M, 
Larson RA, Marcucci G, Bloomfield CD: TET2 mutations occur in over 20% of adults with de novo 
cytogenetically normal Acute Myeloid Leukemia, and their prevalence increases with age: A Cancer 
and Leukemia Group B Study. Haematologica. 95(S2):12-13 (Abstract #0030) 2010. 
 
24 Becker H, Marcucci G, Maharry K, Radmacher MD, Wu Y, Mrozek K, Whitman SP, Margeson D, 
Holland K, Schwind S, Metzeler KH, Powell B, Carter T, Kolitz J, Wetzler M, Carroll A, Baer M, Moore 
J, Caligiuri M, Larson RA, Bloomfield CD: CEBPA double mutations impact favorably on the outcome 
of older adults with wild-type NPM1 cytogenetically normal Acute Myeloid Leukemia and are 
associated with distinct gene and microRNA expression. Haematologica. 95(S2):247-248 (Abstract 
#0593) 2010. 
 
25 Rodriguez B, Tam HH, Frankhouser D, Trimarchi M, Murphy M, Kuo C, Parikh D, Ball B, Schwind S, 
Curfman J, Blum W, Marcucci G, Yan P:  A Scalable, Flexible Workflow for MethylCap-Seq Data 
Analysis. 2011; Unpublished conference proceedings; Gensips 2011 December 4-6, San Antonio, 
Texas, USA 
 
26 Edwards CG, Maharry K, Mrózek K, Schwind S, Paschka P, Nicolet D, Kohlschmidt J, Prior TW, Wu 
YZ, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, 
Bloomfield CD: Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 
Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16). Blood 
118:1077-1077 (Abstract #2514) 2011. 
 
27 Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Whitman SP, 
Metzeler KH, Mrózek K, Wu YZ, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, 
Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD. MiR-3151, a Novel MicroRNA 
Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on 
the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid 
Leukemia (CN-AML). Blood 118:635-635 (Abstract #1462) 2011. 
 
28 Huang X, Schwind S, Yu B, Pang J, Santhanam R, Chan K, Garzon R, Blum W, Bloomfield CD, Liu S, 
Perrotti D, Lee RJ, Byrd JC, Muthasamy N, Lee LJ, Marcucci G. Targeted Delivery of MicroRNA-29b 
by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating 
Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML). Blood 118:39-39 (Abstract #81) 2011. 
 
29 Mendler JH, Maharry K, Radmacher MD, Mrózek K, Kohlschmidt J, Nicolet D, Becker H, Metzeler KH, 
Schwind S, Whitman SP, Blum W, Powell BL, Kolitz JE, Carter TH, Wetzler M, Moore JO, Carroll AJ, 
Baer MR, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Poor Outcome of RUNX1-Mutated 
(RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) 
and Associated Gene- and MicroRNA (miR) Expression Signatures. Blood 118:1476-1477 (Abstract 
#3454) 2011. 
 
30 Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman 
SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, 
Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. ASXL1 Mutations Identify a High-Risk Subgroup 
of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European 
LeukemiaNet ‘Favorable’ Genetic Category. Blood 118:192-192 (Abstract #417) 2011. 
 
31 Mrózek K, Marcucci G, Maharry K, Nicolet D, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu 
YZ, Kohlschmidt J, Pettenati MJ, Koduru PRK, Heerema NA, Block AW, Patil SR, Baer ME, Kolitz JE, 
Moore JO, Carroll AJ, Larson RA, Bloomfield CD. Prognostic Utility of the European LeukemiaNet 
(ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 
1,550 Patients (Pts). Blood 118:190-191 (Abstract #414) 2011. 
 
32 Walker AR, Metzeler KH, Geyer S, Becker H, Schwind S, Whitman SP, Curfman J, Wu YZ, Perrotti D, 
Klisovic RB, Garzon R, Blum W, Marcucci G: Impact of DNMT3A Mutations on Clinical Response to 
the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML). 
Blood 118:430-430 (Abstract #944) 2011. 
 
153 
 
33 Alachkar H, Santhanam R, Lucas DM, Schwind S, Hickey C, Jiuxia P, Perrotti D, Pan L, Kinghorn AD, 
Marcucci G, Grever MR: Translational research from the tropical forest to the clinic: Silvestrol, a 
natural product from the plant Aglaia foveolata inhibits the expression of tyrosine kinases and shows a 
significant in vivo activity in acute myeloid leukemia (AML). Blood 118:1123-1123 (Abstract #2616) 
2011. 
 
34 Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Nicolet D, Radmacher 
MD, Döhner H, Tanner SM, Bloomfield CD, de la Chapelle A: Heritable polymorphism predisposes to 
high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML). Proceedings 
of the American Association for Cancer Research 53: 316 (Abstract #1307) 2012. 
 
35 Schwind S, Blum W, Liu S, Tarighat SS, Geyer S, Klisovic R, Eisfeld AK, Walker A, Whitman SP, 
Santhanam R, Wu YZ, Jacob S, Caligiuri MA, Grever MR, Perrotti D, Byrd JC, Bloomfield CD, Garzon 
R, Marcucci G. The combination of Bortezomib (BOR) and Decitabine (DEC): A Phase I trial in 
patients (pts) with acute myeloid leukemia (AML) targeting FLT3 expression. Proceedings of the 
American Association for Cancer Research 53: 2 (Abstract #CT-06) 2012. 
 
36 Mims AS, Walker AR, Hoellerbauer P, Huang X, Chan KK, Klisovic RB,  Perrotti D, Caligiuri MA, Byrd 
JC,  Chen CS, Blum W, Garzon R, Schwind S, Marcucci G: AR42, a Histone Deacetylase Inhibitor 
(HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel 
epigenetic-targeting approach in Acute Myeloid Leukemia (AML). Proceedings of the American 
Association for Cancer Research 53: 31 (Abstract #119) 2012. 
 
37 Huang X, Schwind S, Eisfeld AK, Jin Y, Yu B, Hickey CJ, Pang J, Santhanam R, Chan K, Perrotti D,  
Muthusamy N, Byrd JC, Blum W, Bloomfield CD, Liu S, Garzon R, Lee RJ, Lee LJ, Marcucci G: 
Synthetic microRNA-181a nanoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in 
acute myeloid leukemia (AML). Proceedings of the American Association for Cancer Research 53: 
271-272 (Abstract #1111) 2012.  
 
38 Metzeler KH, Maharry K, Kohlschmidt J, Mrózek K, Volinia S, Becker H, Schwind S, Mendler JH, 
Eisfeld AK, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Baer MR, Carroll AJ, Caligiuri MA, 
Stone RM, Marcucci G, Bloomfield CD: A leukemia stem cell gene expression signature associates 
with a distinct microRNA expression profile and worse treatment outcomes in older adults with primary 
cytogenetically normal acute myeloid leukemia. 2012; Presented at the annual meeting 2012 of the 
European Hematology Association (EHA) (Abstract #1128) 
 
39 Xi Zhao X, Wu Y, Wang X, Gallego-Perez D, Boukany PE, Huang X, Schwind S, Marcucci G, Lee LJ: 
CEBPA Mutant Regulates miR-181a Expression in AML Cells: A Single Cell Study by Nanochannel 
Electroporation. 2012. Presented at the annual meeting of the American Institute of Chemical 
Engineers (AIChE) 2012. 
 
40 Huang X, Schwind S, Yu B, Liu S, Pang J, Santhanam R, Wu Y, Chan KK, Blum W,  Bloomfield CD, 
Perrotti D, Garzon R, Byrd JC, Muthusamy N, Lee RJ, Marcucci G, Lee LJ: A Novel Anionic 
Nanoparticle Delivery System for Microrna-29b Targets FLT3 and KIT Receptor Tyrosine Kinase 
Expression in Acute Myeloid Leukemia. 2012. Presented at the annual meeting of the American 
Institute of Chemical Engineers (AIChE) 2012. 
 
41 Huang X, Schwind S, Eisfeld AK, Yu B, Santhanam R, Hoellerbauer P, Jin Y, Hickey CJ, Pang J, 
Chan KK, Perrotti D, Muthusamy N, Byrd JC, Blum W,  Bloomfield CD, Liu S, Garzon R, Lee RJ, Lee 
LJ, Marcucci G: Therapeutic Targeting of the RAS-Pathway by Synthetic miR-181a Nanoparticles in 
Acute Myeloid Leukemia (AML). Presented at the annual meeting of the American Society of 
Hematology (ASH) 2012 (Abstract #2422).  
 
42 Alachkar H, Maharry K, Santhanam R, Neviani, P, Volinia S, Kohlschmidt J, Metzeler KH, Dorrance 
AD, Schwind S, Becker H, Mendler JH, MD, Eisfeld AK, Whitman S, Mrózek K, Garzon R, Perrotti, D, 
Caligiuri, Stone RM, Marcucci G, Bloomfield CD: SPARC contributes to Leukemia Growth and 
Aggressive Disease in Acute Myeloid Leukemia (AML). Presented at the annual meeting of the 
American Society of Hematology (ASH) 2012 (Abstract #773). 
 
43 Marcucci G, Maharry K, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschimdt J, Whitman 
S, Mendler, JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, 
154 
 
Caligiuri,MA, Stone RM, Bloomfield CD: The Clinical Role of Micrornas (miRs) in Cytogenetically 
Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-
Risk Patients (Pts Presented at the annual meeting of the American Society of Hematology (ASH) 
2012 (Abstract #1387). 
 
44 Whitman S, Kohlschmidt J, Maharry K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mrózek K, 
Mendler JH, Eisfeld AK, Volinia S, Powell BL, Carter TH, Kolitz JE, Stone RM, Park IK, Caligiuri MA, 
Marcucci G, Bloomfield CD: Adverse Prognostic Impact of GAS6 Expression in De Novo 
Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance). 
Presented at the annual meeting of the American Society of Hematology (ASH) 2012 (Abstract 
#1293).  
 
45 Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Vijayasaradhi UV, Liu Z, Schwind S, Mims AS, 
Klisovic RB, Walker A, Grever MR, Villalona-Calero M, Byrd JC, Garzon R, Blum W, Chan KK, 
Marcucci G: Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel 
Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia 
(AML). Presented at the annual meeting of the American Society of Hematology (ASH) 2012 (Abstract 
#3578). 
 
46 Blum W, Klisovic RB, Walker A, Schwind S, Jiang Y, Wang J, Phelps M, Geyer S, Devine SM, Walsh 
K, Vasu S, Curfman JP, Schaaf L, Garr C, Kefauver C, Byrd JC, Grever MR, Garzon R, Marcucci G: 
Priming of miR-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial 
of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine. 2012; Presented at the annual meeting 
of the American Society of Hematology (ASH) 2012 (Abstract #2619).  
 
47 Motiwala T, Roy S, Liu S, Schwind S, Claus R, Mo X, Garzon R, Döhner H, Döhner K, Jarjoura D, 
Plass C, Marcucci G, Jacob ST: Aberrant Epigenetic Suppression of the Ptprot Gene Encoding a 
Protein Tyrosine Phosphatase Targeting KIT in Acute Myeloid Leukemia. Presented at the annual 
meeting of the American Society of Hematology (ASH) 2012 (Abstract #1322). 
 
48 Jentzsch M, Lange T, Krahl R, Franke GN, Schakols K, Cross M, Vucinic V, Al-Ali HK, Niederwieser 
D, Schwind S: Prognostic significance of aberrant expression of BAALC, ERG and MN1 in patients 
with acute myeloid leukaemia undergoing allogenic haematopoietic cell transplantation with reduced-
intensity conditioning. Presented at the annual meeting of the European Group for Blood and Marrow 
Transplantation (EBMT) 2013 (Abstract #P1102). 
 
49 Schwind S, Jentzsch M, Lange T, Pönisch W, Heyn S, Vucinic V, Franke GN, Krahl R, Jäkel N, Al-Ali 
H, Cross M, Behre G, Marcucci G, Bloomfield C, Niederwieser D: Low pre-treatment miR-181a-1 and 
miR-181a-2 expression associates with relapse in intermediate risk acute myeloid leukemia (AML) 
after reduced-intensity conditioning (RIC) allogeneic transplantation. Presented at the annual meeting 
of the European Haematology Association (EHA) 2013 (Abstract #P362). 
 
50 Niederwieser C, Kohlschmidt J, Maharry K, Mrózek K, Metzeler KH, Volinia S, Yan P, Frankhouser D, 
Whitman SP, Becker H, Eisfeld AK, Schwind S, Curfman J, Wu YZ, Baer MR, Powell BL, Kolitz JE, 
Moore JO, Carter TH, Marcucci G, Bloomfield CD: High expression of DNMT3B negatively impacts on 
clinical outcome of older patients (pts) with primary cytogenetically normal (CN) acute myeloid 
leukemia (AML) [CALGB 20202 (ALLIANCE)]. Presented at the annual meeting of the European 
Haematology Association (EHA) 2013 (Abstract #S1168). 
 
51 Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker C, Jarvinen T, Leffel B, Perrotti D, 
Marcucci G, Bloomfield C, de la Chapelle A. Overexpression of intronic miR-3151 and its host gene 
BAALC increases leukemogenesis in acute myeloid leukemia (AML) by direct deregulation of TP53 
and may be targeted by bortezomib. Presented at the annual meeting of the European Haematology 
Association (EHA) 2013 (Abstract #P020). 
 
52 Jentzsch M, Lange T, Krahl R, Franke GN, Schakols K, Cross M, Al-Ali HK, Vucinic V, Niederwieser 
D, Schwind S: Low BAALC expression associates with longer survival in acute myeloid leukemia 
(AML) patients (pts) undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced-
intensity conditioning (RIC). Presented at the annual meeting of the Deutsche Gesellschaft für 
Hämatologie und Onkologie (DGHO) 2013 (Abstract #V444). 
 
155 
 
53 Schwind S, Jentzsch M, Lange T, Pönisch W, Heyn S, Vucinic V, Franke GN, Krahl R, Jäkel N, Al-Ali 
HK, Cross M, Behre G, Marcucci G, Bloomfield CD, Niederwieser D: High pretreatment miR-181a-1 
and/or miR-181a-2 expression in intermediate risk acute myeloid leukemia (AML) patients (pts) 
associates with lower relapse rates after reduced-intensity conditioning (RIC) allogeneic hematopoietic 
cell transplantation (HCT). Presented at the annual meeting of the Deutsche Gesellschaft für 
Hämatologie und Onkologie (DGHO) 2013 (Abstract #V652). 
 
54 Papaioannou D, Maharry K, Mrózek K, Becker H, Metzeler KH, Mendler JH, Whitman SP, Eisfeld AK, 
Schwind S, Wu YZ, Nicolet D, Kolitz JE, Baer MR, Powell BL, Bucci D, Carroll AJ, Volinia S, Stone 
RM, Marcucci G, Bloomfield CD: Differential Clinical Impact of Gene Mutations and Their 
Combinations in Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Presented at the 
annual meeting of the American Society of Hematology (ASH) 2013 (Abstract #2540). 
 
55 Namasu CY, Gerloff D, Wurm AA, Braeuer-Hartmann D, Hartmann JU, Katzerke C, Schwind S, Hilger 
N, Fricke S, Niederwieser D, Behre G: ABR, a novel inducer of transcription factor C/EBPα, is 
necessary for myeloid differentiation and a prognostic factor in acute myeloid leukemia. Presented at 
the annual meeting of the American Society of Hematology (ASH) 2013 (Abstract #3814). 
 
56 Bill M, Jentzsch M, Lange T, Kloss L, Krahl R, Franke GN, Fricke S, Vucinic V, Pönisch W, Al-Ali HK, 
Cross M, Behre G, Niederwieser D, Schwind S: Prognostic Significance of EVI1 Expression in Acute 
Myeloid Leukemia Patients with Intermediate and Adverse Cytogenetic Risk Undergoing Allogeneic 
Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. Presented at the annual 
meeting of the American Society of Hematology (ASH) 2013 (Abstract #3383). 
 
57 Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, 
Niederwieser D, Sayer H. Lines of pre-treatment and blast count prior to HCT is predictive for survival 
in refractory AML patients treated with FLAMSA-RIC. Presented at the annual meeting of the 
European Group for Blood and Marrow Transplantation (EBMT) 2014 (Abstract # PH-P020). 
 
58 Jentzsch M, Lange T, Bill M, Krahl R, Franke GN, Schakols K, Cross M, Behre G, Vucinic V, 
Niederwieser D, Schwind S. Patients with acute myeloid leukemia undergoing reduced-intensity 
conditioning allogeneic hematopoietic stem cell transplantation: The prognostic impact of aberrant 
BAALC, ERG and MN1 expression levels. Presented at the 120th Annual Meeting 2014 of the 
Deutsche Gesellschaft für Innere Medizin (DGIM) (#P038). 
 
59 Bill M, Jentzsch M, Lange T, Kloss L, Krahl R, Franke GN, Fricke S, Vucinic V, Pönisch W, Al-Ali HK, 
Cross M, Behre G, Niederwieser D, Schwind S: Prognostic Significance of EVI1 Expression in Acute 
Myeloid Leukemia Patients with Intermediate and Adverse Cytogenetic Risk Undergoing Allogeneic 
Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. Presented at the 120th 
Annual Meeting 2014 of the Deutsche Gesellschaft für Innere Medizin (DGIM) (#P040). 
 
60 Weidner H, Bill B, Wildenberger K, Jentzsch M, Kloss L, Schmalbrock L, Cross M, Fricke S, Behre G, 
Schmidt E, Niederwieser D, Schwind S. The adverse predictor ERG is down-regulated by miR-9 in 
Acute Myeloid Leukemia. Presented at the 120th Annual Meeting 2014 of the Deutsche Gesellschaft 
für Innere Medizin (DGIM) (#P033). 
 
61 Bill M, Schmalbrock L, Jentzsch M, Schubert K, Wildenberger K, Weidner H, Pönisch W, Vucinic V, 
Franke GN, Cross M, Behre G, Niederwieser D, Schwind S. Prognostic significance of IDH mutations 
in acute myeloid leukemia (AML) patients undergoing hematopoietic stemcell transplantation (HCT) 
after reduced intensity conditioning (RIC). Presented at the Annual Meeting 2014 of The European 
Hematology Association (EHA), Haematologica 2014;99(s1) 167. 
 
62 Jentzsch M, Bill M, Leiblein S, Weidner H, Wildenberger K, Cross M, Pless M, Bergmann U, Nehring-
Vucinic C, Jäkel N, Krahl R, Pönisch W, Franke GN, Vucinic V, Behre G, Niederwieser D, Schwind S. 
High burden of CD34+/CD38- cells predicts worse outcome in acute myeloid leukemia (AML) patients 
after allogeneic stem cell transplantation (HCT) with reduced intensity conditioning (RIC). Presented at 
the Annual Meeting 2014 of The European Hematology Association (EHA), Haematologica 
2014;99(s1) 166-167. 
 
63 Schmalbrock L, Bill M, Jentzsch M, Schubert K, Wildenberger K, Weidner H, Pönisch W, Vucinic V, 
Franke GN, Cross M, Behre G, Niederwieser D, Schwind S. Isocitrate dehydrogenase (IDH) 
156 
 
mutations (mut) in acute myeloid leukemia (AML) patients (pts) with adverse karyotype undergoing 
hematopoietic stemcell transplantation (HCT) after reduced intensity conditioning (RIC) are associated 
with a favorable outcome. Presented at the DGHO annual meeting 2014 (Abstract #V110). 
 
64 Tumewu T, Franke G-N, Schwind S, Jäkel N, Heyn S, Pönisch W, Al-Ali HK, Leiblein S, Krahl R, 
Jentzsch M, Behre G, Niederwieser D, Vucinic V. Allogeneic stem cell transplantation (HCT) with 
reduced intensity conditioning (RIC) is a feasible therapeutic option in older or comorbide patients (pts) 
with acute lymphoblastic leukemia (ALL). Presented at the DGHO annual meeting 2014 (Abstract 
#P174). 
 
65 Jentzsch M, Bill M, Leiblein S, Weidner H, Schmalbrock L, Wildenberger K, Cross M, Pleß M, 
Bergmann U, Nehring-Vucinic N, Jäkel N,  Krahl R,  Pönisch W, Franke GN, Vucinic V, Behre G, 
Niederwieser D Schwind S. A high CD34+/CD38-cell burden at diagnosis of acute myeloid leukemia 
predicts worse outcome in patients undergoing reduced intensity conditioning allogeneic stem cell 
transplantation. Presented at the DGHO annual meeting 2014 (Abstract #V150). 
 
66 Weidner H, Bill M, Schmalbrock L, Jentzsch M, Kloss L, Gaber T, Schubert K, Wildenberger K, Gerloff 
D, Vucinic V, Franke GN, Lange T, Cross M, Fricke S, Behre G, Niederwieser D, Schwind S. High 
Expression of miR-9 Down-regulates the Poor Outcome Prognosticator ERG and Associates with 
Reduced Relapse-rates in Acute Myeloid Leukemia. Presented at the annual meeting of the American 
Society of Hematology (ASH) 2014 (Abstract #1575). 
 
67 Gaber T, Bill M, Jentzsch M, Schubert K, Weidner H, Kloss L, Schmalbrock L, Wildenberger K, 
Pönisch W, Vucinic V, Franke GN, Lange T, Cross M, Behre G, Niederwieser D, Schwind S. 
Prognostic Implications of Pri-MicroRNA-320a Expression in Acute Myeloid Leukemia Patients. 
Presented at the annual meeting of the American Society of Hematology (ASH) 2014 (Abstract 
#1037). 
 
68 Schwind S, Jentzsch M, Bill M, Schubert K, Schmalbrock L, Weidner H, Kloss L, Gaber T, 
Wildenberger K, Pönisch W, Vucinic V, Franke GN, Lange T, Cross M, Behre G, Niederwieser D. High 
pri-miR-181a-1 and pri-miR-181a-2 Expression Associates with Improved Outcomes in Patients with 
Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity 
Conditioning. Presented at the annual meeting of the American Society of Hematology (ASH) 2014 
(Abstract #732). 
 
69 Hartmann J, Braeuer-Hartmann D, Gerloff D, Katzerke C, Wurm AA, Müller-Tidow C, Schwind S, 
Tenen DG, Niederwieser D, Behre G. The G-CSF induced miR-143 targets MAPK-family proteins and 
is a prognostic factor for RIC-transplanted AML patients. Presented at the annual meeting of the 
American Society of Hematology (ASH) 2014 (Abstract #2200). 
 
70 Jentzsch M, Bill M, Niederwieser D, Schwind S. miR-181a Expression in Acute Myeloid Leukaemia. 
Treatment Strategies Hematology, 2014 Volume 4, Issue 2 (49-55). 
 
71 Bill M, Weidner H, Schwind S. MikroRNA-9 als Modulator der ERG-Expression in der akuten 
myeloischen Leukämie. Leukämie Rundbrief, 2014 19 (20-21). 
 
72 Bonifacio L, Schmalbrock L, Bill M, Jentzsch M, Schubert K, Wildenberger K, Kloss L, Weidner H, 
Gaber T, Pönisch W, Vucinic V, Franke GN, Lange T, Cross M, Behre G, Niederwieser D, Schwind S. 
Exon 23 DNA methyltransferase 3A gene mutations in patients with acute myeloid leukemia receiving 
hematopoietic stem cell transplantation after non myeloablative conditioning. Presented at the annual 
meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2015 (Abstract #P103). 
 
73 Bill M, Jentzsch M, Schubert K, Wildenberger K, Cross M, Vucinic V, Franke GN, Pönisch W, Behre G, 
Lange T, Niederwieser D, Schwind S. Prognostic impact of the European LeukemiaNet standardized 
reporting system in acute myeloid leukemia patients receiving hematopoietic stem cell transplantation 
after non-myeloablative conditioning. Presented at the annual meeting of the European Group for 
Blood and Marrow Transplantation (EBMT) 2015 (Abstract #P713). 
 
74 Jentzsch M, Bill M, Leiblein S, Schubert K, Pleß M, Bergmann U, Wildenberger K, Schmalbrock L, 
Cross M, Pönisch W, Franke GN, Vucinic V, Behre G, Niederwieser D, Schwind S. The prognostic 
impact of CD34+/CD38- cell burden at diagnosis and during disease course in acute myeloid leukemia 
157 
 
patients undergoing allogeneic stem cell transplantation. Presented at the annual meeting of the 
European Group for Blood and Marrow Transplantation (EBMT) 2015 (Abstract #P035).  
 
75 Poenisch W, Ploetze M, Holzvogt B, Andrea M, Schliwa T, Bourgeois M, Heyn S, Franke GN, 
Jentzsch M, Leiblein S, Krahl R, Schwind S, Vucinic V, Al-Ali HK, Niederwieser D. Successful Stem 
Cell Mobilization and Autologous Stem Cell Transplantation after Pretreatment consisting of 
Bendamustine, Prednisone and Bortezomib (BPV) in 35 Patients with newly diagnosed/ untreated 
Multiple Myeloma. Presented at the annual meeting of the European Group for Blood and Marrow 
Transplantation (EBMT) 2015 (Abstract #P360). 
 
76 Bill M, Jentzsch M, Schubert K, Lange T, Grimm J, Knyrim M, Leiblein S, Franke GN, Vucinic V, 
Pönisch W, Cross M, Behre G, Niederwieser D, Schwind S. EVI1 expression associates with higher 
cumulative incidence of relapse in patients with acute myeloid leukemia receiving hematopoietic cell 
transplantation with nonmyeloablative conditioning. Submitted to the annual meeting of the European 
Hematology Association (EHA) 2015 (Abstract #P336). 
 
77 Poenisch W, Mrachacz H, Khoder N, Plötze M, Holzvogt B, Andrea M, Schliwa T, Heyn S, Franke GN, 
Krahl R, Jentzsch M, Leiblein S, Schwind S, Vucinic V, Niederwieser D. Successful treatment of 
patients with newly diagnosed/untreated light chain multiple myeloma with a combination of 
bendamustine, prednisolone and bortezomib (BPV). Submitted to the annual meeting of the European 
Hematology Association (EHA) 2015. 
 
78 Jentzsch M, Bill M, Leiblein S, Schubert K, Wildenberger K, Pless M, Bergmann U, Weidner H, Knyrim 
M, Grimm J, LangeT, Cross M, Franke GN, Pönisch W, Vucinic V, Behre G, Niederwieser D and 
Schwind S. Prognostic Impact of aberrant MN1 Expression in Patients with Acute Myeloid Leukemia 
(AML) Undergoing Allogeneic Stem Cell Transplantation in Complete Remission after Non-
Myeloablative Conditioning (NMA-SCT). Presented at the DGHO annual meeting 2015 (Abstract 
#V126). 
 
79 Grimm J, Bill M, Weidner H, Knyrim M, Schmalbrock L, Jentzsch M, Schubert K, Wurm A, Gerloff D, 
Cross M, Lange T, Behre G, Niederwieser D and Schwind S. microRNA (miR)-9 directly 
downregulates the oncogenic transcription factor ets related gene (ERG) & high expression associates 
with improved outcomes in acute myeloid leukemia (AML). Presented at the DGHO annual meeting 
2015 (Abstract #V541). 
 
80 Bill M, Jentzsch M, Schubert K, Knyrim M, Grimm J, Cross M, Vucinic V, Franke GN, Pönisch W, Behre 
G, Lange T, Niederwieser D and Schwind S. Non-myeloablative conditioning (NMA) followed by 
hematopoietic stem cell transplantation (HCT) in patients (pts) with acute myeloid leukemia (AML): 
prognostic impact of the european leukemianet (ELN) standardized reporting system. Presented at the 
DGHO annual meeting 2015 (Abstract #V428). 
 
81 Grimm J, Bill M, Kloss L, Jentzsch M, Knyrim M, Schubert K, Günther C, Vucinic V, Franke GN, 
Pönisch W, Behre G, Niederwieser D and Schwind S. Assessment of NPM1 Type A Mutation Burden 
by Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients 
Undergoing Stem Cell Transplantation. Presented at the annual meeting of the American Society of 
Hematology (ASH) 2015 (Abstract #4398). 
 
82 Bill M, Jentzsch M, Schuhmann L, Grimm J, Knyrim M, Schmalbrock L, Schubert K, Cross M, Vucinic 
V, Franke GN, Pönisch W, Behre G, Lange T, Niederwieser D and Schwind S. High Expression of the 
Hedgehog Transcription Factor GLI1 is Associated with Improved Outcomes in Patients with Acute 
Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative 
Conditioning. Presented at the annual meeting of the American Society of Hematology (ASH) 2015 
(Abstract #2032). 
 
83 Knyrim M, Jentzsch M, Bill M, Grimm J, Schubert K, Cross M, Franke GN, Pönisch W, Vucinic V, 
Behre G, Niederwieser D and Schwind S. Prognostic Impact of Aberrant RUNX1 Expression in 
Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell 
Transplantation. Presented at the annual meeting of the American Society of Hematology (ASH) 2015 
(Abstract #3829). 
 
158 
 
84 Jentzsch M, Schuhmann L, Bill M, Leiblein S, Bergmann U, Pleß M, Schubert K, Schmalbrock L, 
Grimm J, Knyrim M, Pönisch W, Vucinic V, Franke GN, Behre G, Niederwieser D and Schwind S. 
Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct 
Biological and Clinical Features in Patients with Acute Myeloid Leukemia undergoing Allogeneic Stem 
Cell Transplantation. Presented at the annual meeting of the American Society of Hematology (ASH) 
2015 (Abstract #2573). 
 
85 Gerloff D, Wurm AA, Hartmann JU, Hilger N, Müller AM, Katzerke C, Bräuer-Hartmann D, Namasu 
CY, Cross M, Schwind S, Krohn K, Fricke S, Niederiweser D and Behre G. Next Generation 
Sequencing and Functional Analysis of Mirna Expression in Acute Myeloid Leukemia Patientes with 
Different FLT3 Mutations: Block of MiR-155 in FLT3-ITD Driven AML Leads to Downregulation of 
Myeloid Blasts in Vivo. Presented at the annual meeting of the American Society of Hematology (ASH) 
2015 (Abstract #2438). 
 
86 Bill M, Kloss L, Jentzsch M, Grimm J, Schubert K, Schulz J, Knyrim M, Cross M, Vucinic V, Behre G, 
Pönisch W, Franke G-N, Niederwieser D and Schwind S. Assessing NPM1 Mutations Type A as 
Minimal Residual Disease Marker by Digital Droplet PCR before Stem Cell Transplantation is a Strong 
Prognostic Factor in Patients with AML. Accepted at the Annual Meeting 2016 of The European 
Hematology Association (Abstract E1497) 
 
87 Grimm J, Dick T, Bill M, Jentzsch M, Schulz J, Schmalbrock S, Bonifacio L, Knyrim M, Schubert K, 
Cross M, Pönisch W, Vucinic V, Behre G, Franke G-N, Niederwieser D and Schwind S. Assessement 
of the Allelic Ratio of DNMT3A R882 Mutations in Acute Myeloid Leukemia by Digital Droplet PCR. 
Accepted at the Annual Meeting 2016 of The European Hematology Association (Abstract E90) 
 
88 Jentzsch M, Bill M, Schumann L, Grimm J, Schulz J, Knyrim M, Franke GN, Behre G, Pönisch W, 
Vucinic V, Müller-Tidow C, Pabst C, Niederwieser D, Schwind S. High Expression of the Stem Cell 
Marker GPR56 is associated with an increased Relapse Incidence in AML after Allogeneic Stem Cell 
Transplantation. Accepted at the Annual Meeting 2016 of The European Hematology Association 
(Abstract S820) 
 
89 Beck J, Heyn S, Gläser D, Schwarzer A, Mügge LO, Uhlig J, Kragl B, Mohren M, Hoffmann FA, Lange 
T, Schliwa T, Zehrfeld T, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Jentzsch M, Schwind S, 
Becker C, Niederwieser D, Poenisch W. Revlimid, Bendamustine and prednisolone (RBP) in 
relapsed/refractory multiple myeloma: final results of a phase II clinical trial; OSHO–#077. Accepted 
for presentation at the annual meeting of the European Hematology Association (EHA) 2016 (Abstract 
E1316) 
 
90 Namasu C, Wurm A, Bräuer-Hartmann D, Hartmann JU, Katzerke C, Gerloff D, Hilger N, Fricke S, 
Schwind S, Christopeit M, Niederwieser D, Behre G.	 ABR, a novel inducer of transcription factor 
C/EPAα, is necessary for myeloid differentiation and a favorable prognostic factor in acute myeloid 
leukemia.	 Accepted for presentation at the annual meeting of the DGHO annual meeting 2016 
(Abstract #P495) 
 
91 Hartmann JU, Bräuer-Hartmann D, Gerloff D, Miroslava K, Kazerke C, Meritxell AJ, Schwind S, 
Wurm, A Bill M, Niederwieser D, Behre G.	 miR-143 targets ERK5 in granulopoiesis and predicts 
outcome of Acute Myeloid Leukemia patients.	Accepted for presentation at the annual meeting of the 
DGHO annual meeting 2016 (Abstract #V753) 
 
92 Wurm A, Zjablovskaja P, Miroslava K, Gerloff D, Bräuer-Hartmann D, Katzerke C, Hartmann JU, 
Fricke, S, Hilger N, Müller AM, Bill M, Schwind S, Tenen DG, Niederwieser D, Meritxell AJ, Behre G. 
Disturbance of the C/EPAα-miR-182 balance impairs granulocytic differentiation and promotes 
development of acute myeloid leukemia.	 Accepted for presentation at the annual meeting of the 
DGHO annual meeting 2016 (Abstract #V831) 
 
93 Grimm G, Dick T, Bill M, Jentzsch M, Schulz J, Schmalbrock L, Bonifacio L, Knyrim M, Schubert K, 
Cross M, Pönisch W, Vucinic V, Behre G, Franke GN, Niederwieser D, Schwind S.	The Allelic Ratio 
(AR) of DNMT3A R882 Mutations (Mut) Determined by Digital Droplet PCR (ddPCR) is a Potential 
Prognostic Factor in Acute Myeloid Leukemia (AML). Accepted for presentation at the annual meeting 
of the DGHO annual meeting 2016 (Abstract #	V348) 
 
159 
 
94 Gaber T, Bill M, Jentzsch M, Schubert K, Weidner H, Grimm J, Schulz J, Kloss L, Schmalbrock L, 
Bonifacio L, Wildenberger K, Pönisch W, Vucinic V, Franke GN, Lange T, Cross M, Behre B, 
Niederwieser D, Schwind S.	 Differential Expression of Pri-miR-320a Impacts on Outcome in Acute 
Myeloid Leukemia Patients Undergoing Non-Myeloablative Allogenic Stem Cell Transplantation. 
Accepted for presentation at the annual meeting of the DGHO annual meeting 2016 (Abstract #	P190) 
 
95 Jentzsch M, Bill M, Schuhmann L, Leiblein S, Schubert K, Grimm J, Bergmann U, Pleß M, 
Schmalbrock L, Schulz J, Knyrim M, Franke GN, Behre G, Pönisch W, Vucinic V, Niederwieser D, 
Schwind S.	 The Surface Antigen Profile in Patients (pts) with Acute Myeloid Leukemia (AML) 
Identifies Subgroups Characterized by Distinct Biological and Clinical Features. Accepted for	
presentation at the annual meeting of the DGHO annual meeting 2016 (Abstract #	V783) 
 
96 Jentzsch M, Bill M, Schumann L, Grimm J, Schulz J, Knyrim M, Franke GN, Behre G, Pönisch W, 
Vladan V, Müller-Tidow C, Pabst C, Niederwieser D, Schwind S. High Expression of the Stem Cell 
Marker GPR56 Associates With an Increased Relapse Incidence in Acute Myeloid Leukemia (AML) 
Patients (pts) Undergoing Allogeneic Stem Cell Transplantation (HSCT).	Accepted for	presentation at 
the annual meeting of the DGHO annual meeting 2016 (Abstract #	V1013) 
 
97 Bill M, Kloss L, Jentzsch M, Grimm J, Schubert K, Schulz J, Knyrim M, Cross M, Vucinic V, Behre G, 
Pönisch W, Franke GN, Niederwieser D, Schwind S. NPM1 Type A mutations as minimal residual 
disease marker in acute myeloid leukemia patients before allogeneic stem cell transplantation 
determined by high sensitive and specific digital droplet PCR is a strong prognosticator for outcome. 
Accepted for	presentation at the annual meeting of the DGHO annual meeting 2016 (Abstract #V481) 
 
98 Bill M, Jentzsch M, Schuhmann L, Grimm J, Knyrim M, Schmalbrock L, Schubert K, Cross M, Vucinic 
V, Franke GN, Pönisch W, Behre G, Lange T, Niederwieser D, Schwind S. The prognostic impact of 
differential GLI1 expression in patients with Acute Myeloid Leukemia after Hematopoietic non-
myeloablative conditioning and stem cell transplantation. Accepted for presentation at the annual 
meeting of the DGHO annual meeting 2016 (Abstract #	V1012) 
 
99 Grimm J, Jentzsch M, Bill M, Schulz J, Schubert K, Beinicke S, Häntschel J, Schuhmann L, Cross M, 
Vucinic V, Pönisch W, Behre G, Franke GN, Niederwieser D, Schwind S. High Expression of ZBTB7A 
at Diagnosis Associated with Inferior Outcome in Acute Myeloid Leukemia Patients Receiving 
Hematopoietic Stem Cell Transplantation. Presented at the annual meeting of the American Society of 
Hematology (ASH) 2016 (Abstract #5092). 
 
100 Bill M, Jentzsch M, Schulz J, Schubert K, Grimm J, Schmalbrock LK, Bonifacio L, Beinicke S, 
Häntschel J, Pönisch W, Behre G, Vucinic V, Lange T, Franke GN, Niederwieser D, Schwind S. 
Absolute Quantification of Pre-microRNA-155 Copy Numbers By Digital Droplet PCR Identifies Acute 
Myeloid Leukemia (AML) Patients with Adverse Outcome. Presented at the annual meeting of the 
American Society of Hematology (ASH) 2016 (Abstract #1698). 
 
101 Jentzsch M, Bill M, Schulz J, Grimm J, Beinicke S, Schubert K, Häntschel J, Wildenberger K, 
Schmalbrock LK, Bonifacio L, Pönisch W, Behre G, Franke GN, Lange T, Vucinic V, Niederwieser D, 
Schwind S. High Blood BAALC Copy Numbers Determined By Digital Droplet PCR at Timepoint of 
Allogeneic Transplantation in Complete Remission Predicts Relapse in Patients with Acute Myeloid 
Leukemia. Presented at the annual meeting of the American Society of Hematology (ASH) 2016 
(Abstract #517). 
 
102 Ramdohr F, Bill M, Jentzsch M, Schubert K, Grimm J, Schulz J, Schuhmann L, Schmalbrock LK, 
Bonifacio L, Beinicke S, Häntschel J, Pönisch W, Vucinic V, Franke GN, Lange T, Cross M, Behre G, 
Niederwieser D, Schwind S. Biological Associations and Clinical Impact of Differential Expression of 
the Pre-Mir-29a/b-1 and Pre-Mir-29b-2/C Clusters in Acute Myeloid Leukemia. Presented at the 
annual meeting of the American Society of Hematology (ASH) 2016 (Abstract #5110). 
 
103 Eisfeld AK, Kohlschmidt J, Schwind S, Nicolet D, Blachly JS, Orwick S, Shah C, Bainazar M, 
Kroll K, Walker CJ, Carroll AJ, Powell BL, Stone RM, Kolitz JE, Baer MR, Chapelle Adl, Mrózek K, 
Byrd JC, Bloomfield CD. CCND1 and CCND2 Mutations Are Frequent in Adults with Core-Binding 
Factor Acute Myeloid Leukemia (CBF-AML) with t(8;21)(q22;q22). Presented at the annual meeting of 
the American Society of Hematology (ASH) 2016 (Abstract #2740). 
 
160 
 
104 Ramdohr F, Franke GN, Jentzsch M, Pönisch W, Michael C, Heyn S, Wang SY, Behre G, 
Leiblein S, Schwind S, Niederwieser D, Vucinic V. Outcome of chronic lymphocytic leukemia patients 
undergoing non-myeloablative allogenic stem cell transplantation after treatment with the bruton 
tyrosine kinase inhibitor Ibrutinib. Accepted for presentation at the annual meeting of the European 
Hematology Association (EHA) 2017 (Abstract #3637) 
 
105 Jentzsch M, Bill M, Schulz J, Grimm J, Häntschel J, Beinicke S, Schubert K , Pönisch W, Behre 
G, Franke GN, Lange T, Vucinic V, Niederwieser D, Schwind S. Blood BAALC and MN1 copy number 
assessment by digital droplet PCR prior to allogeneic transplantation predicts relapse in acute myeloid 
leukemia patients. Accepted for presentation at the annual meeting of the European Hematology 
Association (EHA) 2017 (Abstract #2329) 
 
106  Jentzsch M, Bill M, Schuhmann L, Grimm J, Schulz J, Schubert K, Knyrim M, Schmalbrock L, 
Beinicke S, Häntschel J, Pönisch W, Vucinic V, Franke GN, Behre G, Niederwieser D, Schwind S. 
Unsupervised hierarchical clustering of surface antigen expression identifies normal karyotype AML 
patients with distinct disease characteristics and poor outcome. Accepted for presentation at the 
ASCO annual meeting 2017 (Abstract #7042) 
 
107 Grimm J, Jentzsch M, Bill M, Schulz J, Schubert K, Beinicke S, Häntschel J, Schumann L, Cross 
M, Vucinic V, Pönisch W, Behre G, Franke GN, Niederwieser D, Schwind S.	 High Expression of 
ZBTB7A is a Marker for Poor Prognosis in Acute Myeloid Leukemia (AML) patients (pts) Receiving 
Hematopoietic Stem Cell Transplantation (HSCT). Submitted for presentation at the annual meeting of 
the DGHO 2017. 
 
108 Jentzsch M, Bill M, Schulz J, Grimm J, Häntschel J, Beinicke S, Schubert K, Pönisch W, Behre G, 
Franke GN, Lange T, Vucinic V, Niederwieser D, Schwind S. High blood BAALC copy numbers 
assessed by digital droplet PCR prior to allogeneic stem cell transplantation (HSCT) predicts relapse 
in Acute Myeloid Leukemia (AML) patients. Submitted for presentation at the annual meeting of the 
DGHO 2017. 
 
 
 
 
 
 
 
161 
 
8. CURRICULUM VITAE 	
PERSÖNLICHE DATEN 
 
Name: Dr. med. Sebastian Schwind   
Geburtsdatum:  5. Januar 1977 
Geburtsort: Berlin 
Staatsangehörigkeit: Deutsch 
 
SCHULISCHE AUSBILDUNG  
 
1983-1989 Wetzlargrundschule in Berlin 
1989-1996 Leonardo-da-Vinci Gymnasium in Berlin 
 
STUDIUM 
 
1996-2003 Studium der Humanmedizin an der Feien Universität Berlin 
März 1999 Famulatur in der Gefäßchirurgie, Reutingen 
März 2000 Famulatur in der Traumalogie, Berlin 
August 2000 Famulatur in der Endokrinologie, Berlin 
März 2001 Famulatur in der plastischen Chirurgie, Kap Stadt, Südafrika 
September 2001 Famulatur in der klinischen Pharmakologie, Berlin 
Oktober 2002- Februar 2003 Praktisches Jahr (1.Tertial) in der Inneren Medizin, 
 Kantonsspital Aarau, Aarau, Schweiz 
Februar 2003- Juni 2003 Praktisches Jahr (2. Tertial) in der Anästhesiologie 
 Klinikum Neuköln, Berlin 
Juni 2003- September 2003 Praktisches Jahr (3. Tertial) in der Allgemeinchirurgie, 
 Universitätsklinikum Benjamin Franklin, Berlin 
               
PROMOTION 	
Titel: „The prognostic Impact of microRNA-181a expression levels in patients with cytogenetically normal 
acute myeloid leukemia”;  
Note: summa cum laude 	
BERUFLICHER WERDEGANG 
 
2004- 2005 Medical Advisor/ Product Manager bei 
 Sanofi-Synthelabo, Berlin 
 Internal Medicine und Neurology Drugs 
 
Seit November 2005  Arzt in Weiterbildung 
 Department für Innere Medizin, Neurologie und Dermatologie 
 Selbststäige Abteilung für Hämatologie und Internistische Onkologie, 
 Hämostaseologische Ambulanz 
 
April 2008– August 2012  Research Fellowship an der Ohio State University (OSU), Columbus,  
          OH; USA; Comprehensive Cancer Center 
 
 			
	
	
162 
 
 
MITGLIEDSCHAFTEN 	
Deutsche Gesellschaft für Innere Medizin (DGIM) 
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) 
European Hematology Association (EHA)  
 
GUTACHTERTÄTIGKEIT  
 
Leukemia 
Leukemia Research 
Onkologie  
The International Journal of Biochemistry & Cell Biology 
 
AUSZEICHNUNGEN 
 
2009 ASCO Cancer Foundation Merit Award 
2010 AACR-GlaxoSmithKline Outstanding Clinical Scholar Award 
2011 EHA-ASH Translational Research Training in Hematology Award  
2012 AACR-Aflac, Incorporated Scholar-in-Training Award 
2013 EHA Travel Grant 
2014 Pomblitz-Award of the University of Leipzig, Germany 
 
DRITTMITTEL 
 
Stiftung Leukämie des Kompetenznetzes „ Akute und chronische Leukämien“ 
Title: „ Die funktionelle Bedeutung differentieller ERG Expression in der Akuten Myeloischen Leukämie“ 
15.000,00 EUR,  
Duration: 01.05.2013 bis 30.05.2014 
 
Jose Carreras Leukämie Stiftung 
Titel: „Die funktionelle Relevanz und therapeutische Implikationen aberranter ERG Expression in der 
akuten myeloischen Leukämie“ 
198.040,00 EUR 
Duration: 01.09.2014 bis 30.08.2016 
 
Zusammen gegen den Krebs e.V. 
Titel: “Die Rolle von long non-coding RNAs (lncRNAs) in Neoplasien mit IDH und DNMT3A-Mutationen” 
166.600,00 EUR 
Duration: 01.12.2015 bis 30.04.2018  
 
Zusammen gegen den Krebs e.V. 
Titel: “Die Synthese und Testung von Zweit-Generationsinhibitoren des Transkriptionsfaktors ERG” 
179.347,20 EUR, 
Duration: 01.12.2015 bis 30.04.2018 
 
Jose Carreras Leukämie Stiftung 
Titel: „Der Einfluss des molekularen Resterkrankungsnachweises im Krankheitsverlauf auf die Prognose 
von Patienten mit akuter myeloischer Leukämie“ 
156.448,00 EUR 
Duration: 01.02.2017 bis 30.01.2019 
  
163 
 
9. ACKNOWLEDGEMENTS / DANKSAGUNG 
 
Ich möchte diese Gelegenheit nutzen, um mich besonders bei meinem Mentor 
Professor Dr. med. Dr. h. c. Dietger Niederwieser zu bedanken, ohne dessen 
Unterstützung meiner wissenschaftlichen und ärztlichen Tätigkeit es nicht möglich 
gewesen wäre, diese Arbeit zu erstellen, und der mich jederzeit großzügig unterstützte. 
Nach meiner Rückkehr aus den U.S.A. hat er die Rahmenbedingungen und Freiräume 
geschaffen, die für den Aufbau einer eigenen Arbeitsgruppe notwendig waren. Ich 
bedanke mich ebenso herzlich bei Professor Dr. Clara D. Bloomfield für ihre 
kontinuierliche Unterstützung auch über meinen Forschungsaufenthalt in den U.S.A 
hinaus, für Ihre Geduld und anhaltende Anleitung. Die umfangreiche wissenschaftliche 
Förderung, die nachhaltige Betreuung, die ich als außergewöhnlich erleben durfte und 
die vielen Erfahrungen und Eindrücke machen mich mehr als dankbar. 
Ich danke meiner Familie, besonders meinen Eltern, meinen Geschwistern, Madlen und 
Thorsten sowie all meinen Freunden für ihre große Geduld, Unterstützung und Liebe. 
Besonderer Dank gilt auch meiner Arbeitsgruppe für die harte Arbeit an all den 
bisherigen Forschungsprojekten, sowie für das unermüdliche und engagierte 
Vorantreiben der aktuellen, spannenden Projekten: Marius Bill, Juliane Grimm, Janine 
Häntschel, Steffanie Beinicke, Karoline Goldmann, Julia Schulz und natürlich nicht 
zuletzt Madlen Jentzsch. 
Abschließend möchte ich mich ganz herzlich bei allen meinen Kollegen in den U.S.A 
und in Deutschland bedanken und natürlich allen, die die Studie ermöglicht haben, für 
ihre Freundschaft, Ratschläge, Feedback und Unterstützung; und bei so vielen, die den 
gemeinsamen wissenschaftlichen und klinischen Alltag mit Freude und viel Humor stets 
bereichern. 
